tooluniverse-antibody-engineering
Compare original and translation side by side
🇺🇸
Original
English🇨🇳
Translation
ChineseAntibody Engineering & Optimization
抗体工程与优化
AI-guided antibody optimization pipeline from preclinical lead to clinical candidate. Covers sequence humanization, structure modeling, affinity optimization, developability assessment, immunogenicity prediction, and manufacturing feasibility.
KEY PRINCIPLES:
- Report-first approach - Create optimization report before analysis
- Evidence-graded humanization - Score based on germline alignment and framework retention
- Developability-focused - Assess aggregation, stability, PTMs, immunogenicity
- Structure-guided - Use AlphaFold/PDB structures for CDR analysis
- Clinical precedent - Reference approved antibodies for validation
- Quantitative scoring - Developability score (0-100) combining multiple factors
- English-first queries - Always use English terms in tool calls, even if user writes in another language. Respond in user's language
AI引导的抗体优化流程,覆盖从临床前先导分子到临床候选药物的全阶段。包含序列人源化、结构建模、亲和力优化、成药性评估、免疫原性预测及生产可行性分析。
核心原则:
- 先报告后分析 - 在开展分析前先创建优化报告
- 循证分级人源化 - 基于种系序列比对和框架区保留情况打分
- 成药性导向 - 评估聚集性、稳定性、翻译后修饰(PTMs)及免疫原性
- 结构引导 - 利用AlphaFold/PDB结构进行CDR分析
- 临床先例参考 - 以已获批抗体作为验证依据
- 量化评分 - 结合多维度指标的成药性评分(0-100分)
- 工具调用优先英文 - 即使用户使用其他语言提问,工具调用时始终使用英文术语,以用户语言回复
When to Use
适用场景
Apply when user asks:
- "Humanize this mouse antibody sequence"
- "Optimize antibody affinity for [target]"
- "Assess developability of this antibody"
- "Predict immunogenicity risk for [sequence]"
- "Engineer bispecific antibody against [targets]"
- "Reduce aggregation in antibody formulation"
- "Design pH-dependent binding antibody"
- "Analyze CDR sequences and suggest mutations"
当用户提出以下需求时适用:
- "将该鼠源抗体序列人源化"
- "针对[靶点]优化抗体亲和力"
- "评估该抗体的成药性"
- "预测[序列]的免疫原性风险"
- "针对[靶点]设计双特异性抗体"
- "降低抗体制剂的聚集性"
- "设计pH依赖性结合抗体"
- "分析CDR序列并提出突变建议"
Critical Workflow Requirements
关键工作流要求
1. Report-First Approach (MANDATORY)
1. 先报告后分析(强制要求)
-
Create the report file FIRST:
- File name:
antibody_optimization_report.md - Initialize with section headers
- Add placeholder:
[Analyzing...]
- File name:
-
Progressively update as analysis completes
-
Output separate files:
- - All optimized variants
optimized_sequences.fasta - - Before/after comparison
humanization_comparison.csv - - Detailed scores
developability_assessment.csv
-
首先创建报告文件:
- 文件名:
antibody_optimization_report.md - 初始化时添加章节标题
- 加入占位符:
[分析中...]
- 文件名:
-
随分析进度逐步更新
-
输出独立文件:
- - 所有优化变体序列
optimized_sequences.fasta - - 优化前后对比数据
humanization_comparison.csv - - 详细成药性评分
developability_assessment.csv
2. Documentation Standards (MANDATORY)
2. 文档规范(强制要求)
Every optimization MUST include:
markdown
undefined每一项优化必须包含如下格式内容:
markdown
undefinedOptimized Variant: VH_Humanized_v1
优化变体: VH_Humanized_v1
Original Sequence: EVQLVESGGGLVQPGG... (mouse)
Humanized Sequence: EVQLVQSGAEVKKPGA... (human framework)
Humanization Score: 87% human framework
CDR Preservation: 100% (all CDR residues retained)
Metrics:
| Metric | Original | Optimized | Change |
|---|---|---|---|
| Humanness | 62% | 87% | +25% |
| Aggregation risk | 0.58 | 0.32 | -45% |
| Predicted KD | 5.2 nM | 3.8 nM | +27% affinity |
| Immunogenicity | High | Low | -65% |
Source: IMGT germline analysis, IEDB predictions
---原始序列: EVQLVESGGGLVQPGG... (鼠源)
人源化序列: EVQLVQSGAEVKKPGA... (人源框架区)
人源化得分: 87% 人源框架区
CDR保留率: 100% (所有CDR残基均保留)
指标对比:
| 指标 | 原始序列 | 优化后序列 | 变化 |
|---|---|---|---|
| 人源化程度 | 62% | 87% | +25% |
| 聚集风险 | 0.58 | 0.32 | -45% |
| 预测KD值 | 5.2 nM | 3.8 nM | 亲和力提升+27% |
| 免疫原性 | 高 | 低 | -65% |
来源: IMGT种系分析, IEDB预测
---Phase 0: Tool Verification
阶段0: 工具验证
Required Tools
必备工具
| Tool | Purpose | Category |
|---|---|---|
| Germline gene identification | Humanization |
| Human framework sequences | Humanization |
| Antibody structure precedents | Structure |
| Clinical antibody benchmarks | Validation |
| Structure modeling | Structure |
| Epitope identification | Immunogenicity |
| B-cell epitope prediction | Immunogenicity |
| Target antigen information | Target |
| Protein interaction network | Bispecifics |
| Literature precedents | Validation |
| 工具 | 用途 | 分类 |
|---|---|---|
| 种系基因识别 | 人源化 |
| 获取人源框架区序列 | 人源化 |
| 抗体结构先例查询 | 结构分析 |
| 临床抗体基准参考 | 验证 |
| 结构建模 | 结构分析 |
| 表位识别 | 免疫原性 |
| B细胞表位预测 | 免疫原性 |
| 靶点抗原信息获取 | 靶点分析 |
| 蛋白质相互作用网络分析 | 双特异性抗体 |
| 文献先例查询 | 验证 |
Workflow Overview
工作流概览
Phase 1: Input Analysis & Characterization
├── Sequence annotation (CDRs, framework)
├── Species identification
├── Target antigen identification
├── Clinical precedent search
└── OUTPUT: Input characterization
↓
Phase 2: Humanization Strategy
├── Germline gene alignment (IMGT)
├── Framework selection
├── CDR grafting design
├── Backmutation identification
└── OUTPUT: Humanization plan
↓
Phase 3: Structure Modeling & Analysis
├── AlphaFold prediction
├── CDR conformation analysis
├── Epitope mapping
├── Interface analysis
└── OUTPUT: Structural assessment
↓
Phase 4: Affinity Optimization
├── In silico mutation screening
├── CDR optimization strategies
├── Interface improvement
└── OUTPUT: Affinity variants
↓
Phase 5: Developability Assessment
├── Aggregation propensity
├── PTM site identification
├── Stability prediction
├── Expression prediction
└── OUTPUT: Developability score
↓
Phase 6: Immunogenicity Prediction
├── MHC-II epitope prediction (IEDB)
├── T-cell epitope risk
├── Aggregation-related immunogenicity
└── OUTPUT: Immunogenicity risk score
↓
Phase 7: Manufacturing Feasibility
├── Expression level prediction
├── Purification considerations
├── Formulation stability
└── OUTPUT: Manufacturing assessment
↓
Phase 8: Final Report & Recommendations
├── Ranked variant list
├── Experimental validation plan
├── Next steps
└── OUTPUT: Comprehensive report阶段1: 输入分析与特征表征
├── 序列注释(CDR、框架区)
├── 物种识别
├── 靶点抗原表征
├── 临床先例查询
└── 输出: 输入特征表征结果
↓
阶段2: 人源化策略
├── 种系基因比对(IMGT)
├── 框架区选择
├── CDR移植设计
├── 回复突变识别
└── 输出: 人源化方案
↓
阶段3: 结构建模与分析
├── AlphaFold结构预测
├── CDR构象分析
├── 表位定位
├── 结合界面分析
└── 输出: 结构评估结果
↓
阶段4: 亲和力优化
├── 计算突变筛选
├── CDR优化策略
├── 结合界面改进
└── 输出: 亲和力优化变体
↓
阶段5: 成药性评估
├── 聚集倾向性分析
├── PTM位点识别
├── 稳定性预测
├── 表达量预测
└── 输出: 成药性评分
↓
阶段6: 免疫原性预测
├── MHC-II表位预测(IEDB)
├── T细胞表位风险评估
├── 聚集相关免疫原性分析
└── 输出: 免疫原性风险评分
↓
阶段7: 生产可行性分析
├── 表达量预测
├── 纯化方案考量
├── 制剂稳定性分析
└── 输出: 生产评估结果
↓
阶段8: 最终报告与建议
├── 变体排名列表
├── 实验验证方案
├── 后续步骤规划
└── 输出: 综合报告Phase 1: Input Analysis & Characterization
阶段1: 输入分析与特征表征
1.1 Sequence Annotation
1.1 序列注释
python
def annotate_antibody_sequence(sequence):
"""Annotate antibody sequence with CDRs and framework regions."""
# Use IMGT numbering scheme (standard for antibodies)
# CDR definitions (IMGT):
# CDR-H1: 27-38, CDR-H2: 56-65, CDR-H3: 105-117
# CDR-L1: 27-38, CDR-L2: 56-65, CDR-L3: 105-117
annotation = {
'sequence': sequence,
'length': len(sequence),
'regions': {
'FR1': sequence[0:26],
'CDR1': sequence[26:38],
'FR2': sequence[38:55],
'CDR2': sequence[55:65],
'FR3': sequence[65:104],
'CDR3': sequence[104:117],
'FR4': sequence[117:]
}
}
return annotationpython
def annotate_antibody_sequence(sequence):
"""为抗体序列添加CDR和框架区注释。"""
# 使用IMGT编号体系(抗体领域标准)
# CDR定义(IMGT):
# CDR-H1: 27-38, CDR-H2: 56-65, CDR-H3: 105-117
# CDR-L1: 27-38, CDR-L2: 56-65, CDR-L3: 105-117
annotation = {
'sequence': sequence,
'length': len(sequence),
'regions': {
'FR1': sequence[0:26],
'CDR1': sequence[26:38],
'FR2': sequence[38:55],
'CDR2': sequence[55:65],
'FR3': sequence[65:104],
'CDR3': sequence[104:117],
'FR4': sequence[117:]
}
}
return annotation1.2 Species & Germline Identification
1.2 物种与种系基因识别
python
def identify_germline(tu, vh_sequence, vl_sequence):
"""Identify germline genes for VH and VL chains using IMGT."""
# Search for human germline genes
vh_germlines = tu.tools.IMGT_search_genes(
gene_type="IGHV",
species="Homo sapiens"
)
vl_germlines = tu.tools.IMGT_search_genes(
gene_type="IGKV", # or IGLV for lambda
species="Homo sapiens"
)
# Get sequences for top matches
# Calculate identity % for each germline
# Return closest matches
return {
'vh_germline': 'IGHV1-69*01',
'vh_identity': 87.2,
'vl_germline': 'IGKV1-39*01',
'vl_identity': 89.5
}python
def identify_germline(tu, vh_sequence, vl_sequence):
"""利用IMGT识别VH和VL链的种系基因。"""
# 搜索人源种系基因
vh_germlines = tu.tools.IMGT_search_genes(
gene_type="IGHV",
species="Homo sapiens"
)
vl_germlines = tu.tools.IMGT_search_genes(
gene_type="IGKV", # lambda链使用IGLV
species="Homo sapiens"
)
# 获取匹配度最高的序列
# 计算每个种系基因的序列一致性
# 返回最接近的匹配结果
return {
'vh_germline': 'IGHV1-69*01',
'vh_identity': 87.2,
'vl_germline': 'IGKV1-39*01',
'vl_identity': 89.5
}1.3 Clinical Precedent Search
1.3 临床先例查询
python
def search_clinical_precedents(tu, target_antigen):
"""Find approved/clinical antibodies against same target."""
# Search Thera-SAbDab for clinical antibodies
therapeutics = tu.tools.TheraSAbDab_search_by_target(
target=target_antigen
)
approved = [ab for ab in therapeutics if ab['phase'] == 'Approved']
clinical = [ab for ab in therapeutics if 'Phase' in ab['phase']]
return {
'approved_count': len(approved),
'clinical_count': len(clinical),
'examples': approved[:3],
'insights': extract_design_patterns(approved)
}python
def search_clinical_precedents(tu, target_antigen):
"""查找针对同一靶点的已获批/临床阶段抗体。"""
# 在Thera-SAbDab中搜索临床抗体
therapeutics = tu.tools.TheraSAbDab_search_by_target(
target=target_antigen
)
approved = [ab for ab in therapeutics if ab['phase'] == 'Approved']
clinical = [ab for ab in therapeutics if 'Phase' in ab['phase']]
return {
'approved_count': len(approved),
'clinical_count': len(clinical),
'examples': approved[:3],
'insights': extract_design_patterns(approved)
}1.4 Output for Report
1.4 报告输出内容
markdown
undefinedmarkdown
undefined1. Input Characterization
1. 输入特征表征
1.1 Sequence Information
1.1 序列信息
| Property | Heavy Chain (VH) | Light Chain (VL) |
|---|---|---|
| Length | 118 aa | 107 aa |
| Species | Mouse (Mus musculus) | Mouse (Mus musculus) |
| Humanness | 62% | 68% |
| Closest human germline | IGHV1-69*01 (87% identity) | IGKV1-39*01 (90% identity) |
| 属性 | 重链(VH) | 轻链(VL) |
|---|---|---|
| 长度 | 118 aa | 107 aa |
| 物种来源 | 小鼠(Mus musculus) | 小鼠(Mus musculus) |
| 人源化程度 | 62% | 68% |
| 最接近的人源种系基因 | IGHV1-69*01(87%一致性) | IGKV1-39*01(90%一致性) |
1.2 CDR Annotation (IMGT Numbering)
1.2 CDR注释(IMGT编号)
Heavy Chain:
- FR1: 1-26, CDR-H1: 27-38, FR2: 39-55, CDR-H2: 56-65, FR3: 66-104, CDR-H3: 105-117, FR4: 118-128
CDR Sequences:
| CDR | Sequence | Length | Canonical Class |
|---|---|---|---|
| CDR-H1 | GYTFTSYYMH | 10 | H1-13-1 |
| CDR-H2 | GIIPIFGTANY | 11 | H2-10-1 |
| CDR-H3 | ARDDGSYSPFDYWG | 14 | - (unique) |
| CDR-L1 | RASQSISSYLN | 11 | L1-11-1 |
| CDR-L2 | AASSLQS | 7 | L2-8-1 |
| CDR-L3 | QQSYSTPLT | 9 | L3-9-cis7-1 |
重链:
- FR1: 1-26, CDR-H1: 27-38, FR2: 39-55, CDR-H2: 56-65, FR3: 66-104, CDR-H3: 105-117, FR4: 118-128
CDR序列:
| CDR | 序列 | 长度 | 经典构象类别 |
|---|---|---|---|
| CDR-H1 | GYTFTSYYMH | 10 | H1-13-1 |
| CDR-H2 | GIIPIFGTANY | 11 | H2-10-1 |
| CDR-H3 | ARDDGSYSPFDYWG | 14 | -(独特构象) |
| CDR-L1 | RASQSISSYLN | 11 | L1-11-1 |
| CDR-L2 | AASSLQS | 7 | L2-8-1 |
| CDR-L3 | QQSYSTPLT | 9 | L3-9-cis7-1 |
1.3 Target Information
1.3 靶点信息
| Property | Value |
|---|---|
| Target | PD-L1 (Programmed death-ligand 1) |
| UniProt | Q9NZQ7 |
| Function | Immune checkpoint, inhibits T-cell activation |
| Disease relevance | Cancer immunotherapy target |
| 属性 | 数值 |
|---|---|
| 靶点 | PD-L1(程序性死亡配体1) |
| UniProt编号 | Q9NZQ7 |
| 功能 | 免疫检查点,抑制T细胞活化 |
| 疾病相关性 | 肿瘤免疫治疗靶点 |
1.4 Clinical Precedents
1.4 临床先例
Approved antibodies targeting PD-L1:
- Atezolizumab (Tecentriq) - IgG1, approved 2016
- Durvalumab (Imfinzi) - IgG1, approved 2017
- Avelumab (Bavencio) - IgG1, approved 2017
Key insights: All approved anti-PD-L1 antibodies use human IgG1 scaffolds with effector function modifications.
Source: TheraSAbDab, UniProt
---已获批的抗PD-L1抗体:
- Atezolizumab(Tecentriq)- IgG1,2016年获批
- Durvalumab(Imfinzi)- IgG1,2017年获批
- Avelumab(Bavencio)- IgG1,2017年获批
关键启示: 所有已获批抗PD-L1抗体均采用人源IgG1骨架,并对效应功能进行了修饰。
来源: TheraSAbDab, UniProt
---Phase 2: Humanization Strategy
阶段2: 人源化策略
2.1 Framework Selection
2.1 框架区选择
python
def select_human_framework(tu, mouse_sequence, cdr_sequences):
"""Select optimal human framework for CDR grafting."""
# Search IMGT for human germline genes
vh_genes = tu.tools.IMGT_search_genes(
gene_type="IGHV",
species="Homo sapiens"
)
# For each candidate framework:
# 1. Calculate sequence identity to mouse FR
# 2. Check CDR canonical class compatibility
# 3. Assess structural compatibility
# 4. Consider clinical precedents
candidates = []
for gene in vh_genes[:20]: # Top 20 human germlines
gene_seq = tu.tools.IMGT_get_sequence(
accession=gene['accession'],
format='fasta'
)
score = calculate_framework_score(
mouse_fr=extract_framework(mouse_sequence),
human_fr=extract_framework(gene_seq),
cdr_compatibility=check_cdr_compatibility(cdr_sequences, gene_seq)
)
candidates.append({
'germline': gene['name'],
'identity': score['identity'],
'cdr_compatibility': score['cdr_compatibility'],
'clinical_use': count_clinical_uses(gene['name']),
'overall_score': score['total']
})
# Sort by overall score
return sorted(candidates, key=lambda x: x['overall_score'], reverse=True)python
def select_human_framework(tu, mouse_sequence, cdr_sequences):
"""为CDR移植选择最优人源框架区。"""
# 在IMGT中搜索人源种系基因
vh_genes = tu.tools.IMGT_search_genes(
gene_type="IGHV",
species="Homo sapiens"
)
# 对每个候选框架区:
# 1. 计算与鼠源框架区的序列一致性
# 2. 检查CDR经典构象兼容性
# 3. 评估结构兼容性
# 4. 参考临床应用先例
candidates = []
for gene in vh_genes[:20]: # 前20种人源种系基因
gene_seq = tu.tools.IMGT_get_sequence(
accession=gene['accession'],
format='fasta'
)
score = calculate_framework_score(
mouse_fr=extract_framework(mouse_sequence),
human_fr=extract_framework(gene_seq),
cdr_compatibility=check_cdr_compatibility(cdr_sequences, gene_seq)
)
candidates.append({
'germline': gene['name'],
'identity': score['identity'],
'cdr_compatibility': score['cdr_compatibility'],
'clinical_use': count_clinical_uses(gene['name']),
'overall_score': score['total']
})
# 按综合得分排序
return sorted(candidates, key=lambda x: x['overall_score'], reverse=True)2.2 CDR Grafting Design
2.2 CDR移植设计
python
def design_cdr_grafting(mouse_sequence, human_framework, cdr_sequences):
"""Design CDR grafting with backmutation identification."""
# Graft mouse CDRs onto human framework
grafted_sequence = graft_cdrs(
human_framework=human_framework,
mouse_cdrs=cdr_sequences
)
# Identify Vernier zone residues (affect CDR conformation)
vernier_residues = [2, 27, 28, 29, 30, 47, 48, 67, 69, 71, 78, 93, 94]
# Identify potential backmutations
backmutations = []
for pos in vernier_residues:
if mouse_sequence[pos] != human_framework[pos]:
backmutations.append({
'position': pos,
'human_aa': human_framework[pos],
'mouse_aa': mouse_sequence[pos],
'reason': 'Vernier zone - may affect CDR conformation',
'priority': 'High' if pos in [27, 29, 30, 48] else 'Medium'
})
return {
'grafted_sequence': grafted_sequence,
'backmutations': backmutations,
'humanness_score': calculate_humanness(grafted_sequence)
}python
def design_cdr_grafting(mouse_sequence, human_framework, cdr_sequences):
"""设计CDR移植方案并识别回复突变位点。"""
# 将鼠源CDR移植到人源框架区
grafted_sequence = graft_cdrs(
human_framework=human_framework,
mouse_cdrs=cdr_sequences
)
# 识别Vernier区残基(影响CDR构象)
vernier_residues = [2, 27, 28, 29, 30, 47, 48, 67, 69, 71, 78, 93, 94]
# 识别潜在回复突变位点
backmutations = []
for pos in vernier_residues:
if mouse_sequence[pos] != human_framework[pos]:
backmutations.append({
'position': pos,
'human_aa': human_framework[pos],
'mouse_aa': mouse_sequence[pos],
'reason': 'Vernier区 - 可能影响CDR构象',
'priority': '高' if pos in [27, 29, 30, 48] else '中'
})
return {
'grafted_sequence': grafted_sequence,
'backmutations': backmutations,
'humanness_score': calculate_humanness(grafted_sequence)
}2.3 Humanization Scoring
2.3 人源化评分
python
def calculate_humanization_score(sequence, human_germline):
"""Calculate comprehensive humanization score."""
# Framework humanness (% identity to human germline)
fr_identity = calculate_framework_identity(sequence, human_germline)
# T-cell epitope content (lower is better)
tcell_epitope_count = predict_tcell_epitopes(sequence)
# Unusual residues in human context
unusual_residues = count_unusual_residues(sequence)
# Aggregation hotspots
aggregation_motifs = find_aggregation_motifs(sequence)
score = {
'framework_humanness': fr_identity, # 0-100%
'cdr_preservation': 100, # Always 100% initially
'tcell_epitopes': tcell_epitope_count,
'unusual_residues': unusual_residues,
'aggregation_risk': len(aggregation_motifs),
'overall_score': calculate_weighted_score(
fr_identity, tcell_epitope_count, unusual_residues, aggregation_motifs
)
}
return scorepython
def calculate_humanization_score(sequence, human_germline):
"""计算综合人源化评分。"""
# 框架区人源化程度(与人源种系基因的一致性百分比)
fr_identity = calculate_framework_identity(sequence, human_germline)
# T细胞表位含量(越少越好)
tcell_epitope_count = predict_tcell_epitopes(sequence)
# 人源背景下的异常残基数量
unusual_residues = count_unusual_residues(sequence)
# 聚集热点区域
aggregation_motifs = find_aggregation_motifs(sequence)
score = {
'framework_humanness': fr_identity, # 0-100%
'cdr_preservation': 100, # 初始阶段始终为100%
'tcell_epitopes': tcell_epitope_count,
'unusual_residues': unusual_residues,
'aggregation_risk': len(aggregation_motifs),
'overall_score': calculate_weighted_score(
fr_identity, tcell_epitope_count, unusual_residues, aggregation_motifs
)
}
return score2.4 Output for Report
2.4 报告输出内容
markdown
undefinedmarkdown
undefined2. Humanization Strategy
2. 人源化策略
2.1 Framework Selection
2.1 框架区选择
Selected Human Frameworks:
| Chain | Germline | Identity | CDR Compatibility | Clinical Use | Score |
|---|---|---|---|---|---|
| VH | IGHV1-69*01 | 87.2% | Excellent | 127 antibodies | 94/100 |
| VL | IGKV1-39*01 | 89.5% | Excellent | 89 antibodies | 92/100 |
Rationale:
- IGHV1-69*01: Most frequently used human germline in therapeutic antibodies
- High sequence identity minimizes risk of affinity loss
- Excellent CDR canonical class compatibility
- Proven clinical track record
选定的人源框架区:
| 链 | 种系基因 | 序列一致性 | CDR兼容性 | 临床应用次数 | 得分 |
|---|---|---|---|---|---|
| VH | IGHV1-69*01 | 87.2% | 优秀 | 127种抗体 | 94/100 |
| VL | IGKV1-39*01 | 89.5% | 优秀 | 89种抗体 | 92/100 |
选择依据:
- IGHV1-69*01: 治疗性抗体中使用最频繁的人源种系基因
- 高序列一致性可最小化亲和力损失风险
- 与CDR经典构象高度兼容
- 具备成熟的临床应用记录
2.2 CDR Grafting Design
2.2 CDR移植设计
Grafting Strategy: Direct CDR transfer with Vernier zone optimization
| Region | Source | Sequence | Rationale |
|---|---|---|---|
| FR1 | IGHV1-69*01 | EVQLVQSGAEVKKPGA... | Human framework |
| CDR-H1 | Mouse | GYTFTSYYMH | Retain binding |
| FR2 | IGHV1-69*01 | VKWVRQAPGQGLE... | Human framework |
| CDR-H2 | Mouse | GIIPIFGTANY | Retain binding |
| FR3 | IGHV1-69*01 | RVTMTTDTSTSTYME... | Human framework |
| CDR-H3 | Mouse | ARDDGSYSPFDYWG | Retain binding |
| FR4 | IGHJ4*01 | WGQGTLVTVSS | Human framework |
移植策略: 直接CDR移植结合Vernier区优化
| 区域 | 来源 | 序列 | 依据 |
|---|---|---|---|
| FR1 | IGHV1-69*01 | EVQLVQSGAEVKKPGA... | 人源框架区 |
| CDR-H1 | 鼠源 | GYTFTSYYMH | 保留结合活性 |
| FR2 | IGHV1-69*01 | VKWVRQAPGQGLE... | 人源框架区 |
| CDR-H2 | 鼠源 | GIIPIFGTANY | 保留结合活性 |
| FR3 | IGHV1-69*01 | RVTMTTDTSTSTYME... | 人源框架区 |
| CDR-H3 | 鼠源 | ARDDGSYSPFDYWG | 保留结合活性 |
| FR4 | IGHJ4*01 | WGQGTLVTVSS | 人源框架区 |
2.3 Backmutation Analysis
2.3 回复突变分析
Identified Vernier Zone Residues (may require backmutation):
| Position | Human | Mouse | Region | Impact | Priority |
|---|---|---|---|---|---|
| 27 | T | A | CDR-H1 boundary | CDR conformation | High |
| 48 | I | V | FR2 | VH-VL interface | High |
| 67 | A | S | FR3 | CDR-H2 support | Medium |
| 71 | R | K | FR3 | CDR-H2 support | Medium |
| 93 | A | T | FR3 | CDR-H3 base | Medium |
Recommendation: Test versions with/without backmutations at positions 27 and 48
识别的Vernier区残基(可能需要回复突变):
| 位置 | 人源残基 | 鼠源残基 | 区域 | 影响 | 优先级 |
|---|---|---|---|---|---|
| 27 | T | A | CDR-H1边界 | CDR构象 | 高 |
| 48 | I | V | FR2 | VH-VL界面 | 高 |
| 67 | A | S | FR3 | CDR-H2支撑区 | 中 |
| 71 | R | K | FR3 | CDR-H2支撑区 | 中 |
| 93 | A | T | FR3 | CDR-H3基部 | 中 |
建议: 测试包含/不包含27和48位回复突变的变体
2.4 Humanized Sequences
2.4 人源化序列
Version 1: Full humanization (no backmutations)
>VH_Humanized_v1 | 87% human framework
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSSVersion 2: With key backmutations (positions 27, 48)
>VH_Humanized_v2 | 85% human framework + backmutations
EVQLVQSGAEVKKPGASVKVSCKASGYAFTSYYMHWVRQAPGQGLEWMVGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSSHumanization Metrics:
| Metric | Original (Mouse) | v1 (Full) | v2 (Backmut) |
|---|---|---|---|
| Framework humanness | 62% | 87% | 85% |
| CDR preservation | 100% | 100% | 100% |
| Vernier zone match | Mouse | Human | Mixed |
| Predicted affinity | Baseline | 60-80% | 80-100% |
Source: IMGT germline database, CDR analysis
---版本1: 完全人源化(无回复突变)
>VH_Humanized_v1 | 87%人源框架区
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS版本2: 包含关键回复突变(27、48位)
>VH_Humanized_v2 | 85%人源框架区 + 回复突变
EVQLVQSGAEVKKPGASVKVSCKASGYAFTSYYMHWVRQAPGQGLEWMVGIIPIFGTANY
AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS人源化指标:
| 指标 | 原始鼠源序列 | v1(完全人源化) | v2(含回复突变) |
|---|---|---|---|
| 框架区人源化程度 | 62% | 87% | 85% |
| CDR保留率 | 100% | 100% | 100% |
| Vernier区匹配度 | 鼠源 | 人源 | 混合 |
| 预测亲和力 | 基线水平 | 60-80%基线 | 80-100%基线 |
来源: IMGT种系数据库, CDR分析
---Phase 3: Structure Modeling & Analysis
阶段3: 结构建模与分析
3.1 AlphaFold Structure Prediction
3.1 AlphaFold结构预测
python
def predict_antibody_structure(tu, vh_sequence, vl_sequence):
"""Predict antibody Fv structure using AlphaFold."""
# Combine VH and VL with linker
fv_sequence = vh_sequence + ":" + vl_sequence # AlphaFold uses : for chain separator
# Predict structure
prediction = tu.tools.AlphaFold_get_prediction(
sequence=fv_sequence,
return_format='pdb'
)
# Extract pLDDT scores
plddt_scores = extract_plddt(prediction)
# Analyze by region
regions = {
'VH_FR': np.mean([plddt_scores[i] for i in range(0, 26)]),
'CDR_H1': np.mean([plddt_scores[i] for i in range(26, 38)]),
'CDR_H2': np.mean([plddt_scores[i] for i in range(55, 65)]),
'CDR_H3': np.mean([plddt_scores[i] for i in range(104, 117)]),
'VL_FR': np.mean([plddt_scores[i] for i in range(len(vh_sequence), len(vh_sequence)+26)]),
'CDR_L1': np.mean([plddt_scores[i] for i in range(len(vh_sequence)+26, len(vh_sequence)+38)]),
}
return {
'structure': prediction,
'mean_plddt': np.mean(plddt_scores),
'regional_plddt': regions,
'cdr_confidence': np.mean([regions['CDR_H1'], regions['CDR_H2'], regions['CDR_H3']])
}python
def predict_antibody_structure(tu, vh_sequence, vl_sequence):
"""利用AlphaFold预测抗体Fv区结构。"""
# 用连接子拼接VH和VL序列
fv_sequence = vh_sequence + ":" + vl_sequence # AlphaFold使用:作为链分隔符
# 预测结构
prediction = tu.tools.AlphaFold_get_prediction(
sequence=fv_sequence,
return_format='pdb'
)
# 提取pLDDT评分
plddt_scores = extract_plddt(prediction)
# 按区域分析
regions = {
'VH_FR': np.mean([plddt_scores[i] for i in range(0, 26)]),
'CDR_H1': np.mean([plddt_scores[i] for i in range(26, 38)]),
'CDR_H2': np.mean([plddt_scores[i] for i in range(55, 65)]),
'CDR_H3': np.mean([plddt_scores[i] for i in range(104, 117)]),
'VL_FR': np.mean([plddt_scores[i] for i in range(len(vh_sequence), len(vh_sequence)+26)]),
'CDR_L1': np.mean([plddt_scores[i] for i in range(len(vh_sequence)+26, len(vh_sequence)+38)]),
}
return {
'structure': prediction,
'mean_plddt': np.mean(plddt_scores),
'regional_plddt': regions,
'cdr_confidence': np.mean([regions['CDR_H1'], regions['CDR_H2'], regions['CDR_H3']])
}3.2 CDR Conformation Analysis
3.2 CDR构象分析
python
def analyze_cdr_conformation(structure):
"""Analyze CDR loop conformations and canonical classes."""
# Extract CDR coordinates
cdr_coords = extract_cdr_regions(structure)
# Classify canonical structures
cdr_classes = {
'CDR-H1': classify_canonical_structure(cdr_coords['H1']),
'CDR-H2': classify_canonical_structure(cdr_coords['H2']),
'CDR-H3': 'Non-canonical (14 aa)', # Usually unique
'CDR-L1': classify_canonical_structure(cdr_coords['L1']),
'CDR-L2': classify_canonical_structure(cdr_coords['L2']),
'CDR-L3': classify_canonical_structure(cdr_coords['L3'])
}
# Calculate RMSD to known canonical structures
rmsd_values = calculate_canonical_rmsd(cdr_coords, cdr_classes)
return {
'classes': cdr_classes,
'rmsd': rmsd_values,
'confidence': assess_conformation_confidence(rmsd_values)
}python
def analyze_cdr_conformation(structure):
"""分析CDR环构象及经典构象类别。"""
# 提取CDR坐标
cdr_coords = extract_cdr_regions(structure)
# 分类经典构象
cdr_classes = {
'CDR-H1': classify_canonical_structure(cdr_coords['H1']),
'CDR-H2': classify_canonical_structure(cdr_coords['H2']),
'CDR-H3': '非经典构象(14 aa)', # 通常为独特构象
'CDR-L1': classify_canonical_structure(cdr_coords['L1']),
'CDR-L2': classify_canonical_structure(cdr_coords['L2']),
'CDR-L3': classify_canonical_structure(cdr_coords['L3'])
}
# 计算与已知经典构象的RMSD
rmsd_values = calculate_canonical_rmsd(cdr_coords, cdr_classes)
return {
'classes': cdr_classes,
'rmsd': rmsd_values,
'confidence': assess_conformation_confidence(rmsd_values)
}3.3 Epitope Mapping
3.3 表位定位
python
def map_epitope(tu, target_protein, antibody_structure):
"""Identify epitope on target protein."""
# Get target structure or predict
target_info = tu.tools.UniProt_get_protein_by_accession(
accession=target_protein
)
# Search for known epitopes
epitopes = tu.tools.iedb_search_epitopes(
sequence_contains=target_protein,
structure_type="Linear peptide",
limit=20
)
# Search for structural antibody complexes
sabdab_results = tu.tools.SAbDab_search_structures(
query=target_info['protein_name']
)
# Analyze binding interface
interface = {
'epitope_candidates': epitopes,
'structural_precedents': sabdab_results,
'predicted_interface': predict_binding_interface(antibody_structure)
}
return interfacepython
def map_epitope(tu, target_protein, antibody_structure):
"""识别靶点蛋白上的表位。"""
# 获取或预测靶点结构
target_info = tu.tools.UniProt_get_protein_by_accession(
accession=target_protein
)
# 搜索已知表位
epitopes = tu.tools.iedb_search_epitopes(
sequence_contains=target_protein,
structure_type="Linear peptide",
limit=20
)
# 搜索已解析的抗体-靶点复合物结构
sabdab_results = tu.tools.SAbDab_search_structures(
query=target_info['protein_name']
)
# 分析结合界面
interface = {
'epitope_candidates': epitopes,
'structural_precedents': sabdab_results,
'predicted_interface': predict_binding_interface(antibody_structure)
}
return interface3.4 Output for Report
3.4 报告输出内容
markdown
undefinedmarkdown
undefined3. Structure Modeling & Analysis
3. 结构建模与分析
3.1 AlphaFold Predictions
3.1 AlphaFold预测结果
Structure Quality:
| Variant | Mean pLDDT | VH pLDDT | VL pLDDT | CDR pLDDT | Confidence |
|---|---|---|---|---|---|
| Original (Mouse) | 89.2 | 91.4 | 88.7 | 85.3 | High |
| VH_Humanized_v1 | 87.8 | 89.6 | 88.2 | 83.1 | High |
| VH_Humanized_v2 | 88.9 | 90.8 | 88.5 | 84.8 | High |
Regional Confidence (v2):
- Framework regions: 92.3 (very high)
- CDR-H1, H2, L1, L2: 87-91 (high)
- CDR-H3: 78.4 (moderate - expected for unique CDR-H3)
- VH-VL interface: 90.1 (high)
结构质量:
| 变体 | 平均pLDDT | VH pLDDT | VL pLDDT | CDR pLDDT | 置信度 |
|---|---|---|---|---|---|
| 原始鼠源序列 | 89.2 | 91.4 | 88.7 | 85.3 | 高 |
| VH_Humanized_v1 | 87.8 | 89.6 | 88.2 | 83.1 | 高 |
| VH_Humanized_v2 | 88.9 | 90.8 | 88.5 | 84.8 | 高 |
区域置信度(v2变体):
- 框架区: 92.3(极高)
- CDR-H1、H2、L1、L2: 87-91(高)
- CDR-H3: 78.4(中等 - 独特CDR-H3的正常情况)
- VH-VL界面: 90.1(高)
3.2 CDR Conformation Analysis
3.2 CDR构象分析
Canonical Classes (Humanized v2):
| CDR | Length | Canonical Class | RMSD to Class | Status |
|---|---|---|---|---|
| CDR-H1 | 10 | H1-13-1 | 0.8 Å | ✓ Maintained |
| CDR-H2 | 11 | H2-10-1 | 1.1 Å | ✓ Maintained |
| CDR-H3 | 14 | Non-canonical | N/A | Unique structure |
| CDR-L1 | 11 | L1-11-1 | 0.9 Å | ✓ Maintained |
| CDR-L2 | 7 | L2-8-1 | 0.7 Å | ✓ Maintained |
| CDR-L3 | 9 | L3-9-cis7-1 | 1.0 Å | ✓ Maintained |
Assessment: All CDR conformations well-preserved in humanized variants. Low RMSD values indicate minimal structural perturbation from humanization.
经典构象类别(人源化v2变体):
| CDR | 长度 | 经典构象类别 | 与类别的RMSD | 状态 |
|---|---|---|---|---|
| CDR-H1 | 10 | H1-13-1 | 0.8 Å | ✓ 构象保留 |
| CDR-H2 | 11 | H2-10-1 | 1.1 Å | ✓ 构象保留 |
| CDR-H3 | 14 | 非经典构象 | N/A | 独特构象 |
| CDR-L1 | 11 | L1-11-1 | 0.9 Å | ✓ 构象保留 |
| CDR-L2 | 7 | L2-8-1 | 0.7 Å | ✓ 构象保留 |
| CDR-L3 | 9 | L3-9-cis7-1 | 1.0 Å | ✓ 构象保留 |
评估: 人源化变体中所有CDR构象均得到良好保留。低RMSD值表明人源化对结构的干扰极小。
3.3 Epitope Analysis
3.3 表位分析
Known PD-L1 Epitopes (IEDB):
| Epitope | Sequence | Position | Binding Antibodies | Conservation |
|---|---|---|---|---|
| Epitope 1 | LQDAG...VPEPP | 19-113 | Durvalumab, Avelumab | 98% |
| Epitope 2 | FTVT...PGPN | 54-68 | Atezolizumab | 100% |
| Epitope 3 | RLEDL...NVSI | 115-127 | Research Abs | 95% |
Predicted Binding Interface:
- Primary contact residues: CDR-H3 (70%), CDR-H1 (15%), CDR-H2 (10%)
- Secondary contacts: CDR-L3 (5%)
- Estimated buried surface area: 820 Ų
已知PD-L1表位(IEDB):
| 表位 | 序列 | 位置 | 结合抗体 | 保守性 |
|---|---|---|---|---|
| 表位1 | LQDAG...VPEPP | 19-113 | Durvalumab、Avelumab | 98% |
| 表位2 | FTVT...PGPN | 54-68 | Atezolizumab | 100% |
| 表位3 | RLEDL...NVSI | 115-127 | 研究用抗体 | 95% |
预测结合界面:
- 主要接触残基: CDR-H3(70%)、CDR-H1(15%)、CDR-H2(10%)
- 次要接触残基: CDR-L3(5%)
- 预估掩埋表面积: 820 Ų
3.4 Structural Comparison
3.4 结构对比
Superposition with Clinical Antibodies (SAbDab):
| Reference | PDB ID | VH RMSD | VL RMSD | CDR-H3 RMSD | Notes |
|---|---|---|---|---|---|
| Atezolizumab | 5X8L | 1.2 Å | 1.4 Å | 2.8 Å | Similar approach angle |
| Durvalumab | 5X8M | 1.8 Å | 1.5 Å | 3.4 Å | Different epitope |
| Research Ab | 5C3T | 0.9 Å | 1.1 Å | 1.5 Å | Very similar |
Source: AlphaFold, IEDB, SAbDab
---与临床抗体的结构叠加(SAbDab):
| 参考抗体 | PDB编号 | VH RMSD | VL RMSD | CDR-H3 RMSD | 说明 |
|---|---|---|---|---|---|
| Atezolizumab | 5X8L | 1.2 Å | 1.4 Å | 2.8 Å | 结合角度相似 |
| Durvalumab | 5X8M | 1.8 Å | 1.5 Å | 3.4 Å | 结合表位不同 |
| 研究用抗体 | 5C3T | 0.9 Å | 1.1 Å | 1.5 Å | 结构高度相似 |
来源: AlphaFold, IEDB, SAbDab
---Phase 4: Affinity Optimization
阶段4: 亲和力优化
4.1 In Silico Mutation Screening
4.1 计算突变筛选
python
def design_affinity_variants(antibody_structure, target_structure):
"""Design affinity maturation variants using computational screening."""
# Identify interface residues
interface_residues = identify_interface_residues(
antibody_structure,
target_structure,
distance_cutoff=4.5 # Angstroms
)
# Focus on CDR residues
cdr_interface = [res for res in interface_residues if is_cdr_residue(res)]
# Design mutations for each position
variants = []
for position in cdr_interface:
# Try all amino acids except original
for aa in 'ACDEFGHIKLMNPQRSTVWY':
if aa != antibody_structure.sequence[position]:
predicted_ddg = predict_binding_energy_change(
structure=antibody_structure,
mutation=f"{antibody_structure.sequence[position]}{position}{aa}"
)
if predicted_ddg < -0.5: # Favorable change (more negative = better)
variants.append({
'position': position,
'original': antibody_structure.sequence[position],
'mutant': aa,
'predicted_ddg': predicted_ddg,
'predicted_kd_fold': calculate_kd_change(predicted_ddg)
})
# Rank by predicted improvement
return sorted(variants, key=lambda x: x['predicted_ddg'])python
def design_affinity_variants(antibody_structure, target_structure):
"""通过计算筛选设计亲和力成熟变体。"""
# 识别结合界面残基
interface_residues = identify_interface_residues(
antibody_structure,
target_structure,
distance_cutoff=4.5 # 埃
)
# 聚焦CDR区残基
cdr_interface = [res for res in interface_residues if is_cdr_residue(res)]
# 为每个位置设计突变
variants = []
for position in cdr_interface:
# 尝试除原始残基外的所有氨基酸
for aa in 'ACDEFGHIKLMNPQRSTVWY':
if aa != antibody_structure.sequence[position]:
predicted_ddg = predict_binding_energy_change(
structure=antibody_structure,
mutation=f"{antibody_structure.sequence[position]}{position}{aa}"
)
if predicted_ddg < -0.5: # 有利变化(负值越大越好)
variants.append({
'position': position,
'original': antibody_structure.sequence[position],
'mutant': aa,
'predicted_ddg': predicted_ddg,
'predicted_kd_fold': calculate_kd_change(predicted_ddg)
})
# 按预测提升效果排序
return sorted(variants, key=lambda x: x['predicted_ddg'])4.2 CDR Optimization Strategies
4.2 CDR优化策略
python
def cdr_optimization_strategies(cdr_sequence, cdr_name):
"""Identify CDR optimization strategies based on sequence and structure."""
strategies = []
# Strategy 1: Extend CDR for increased contact area
if len(cdr_sequence) < 12 and cdr_name == 'CDR-H3':
strategies.append({
'strategy': 'CDR-H3 extension',
'rationale': 'Add 1-2 residues to increase contact surface',
'expected_impact': '+2-5x affinity improvement',
'examples': ['Extension with Gly-Tyr', 'Extension with Ser-Asp']
})
# Strategy 2: Tyrosine enrichment
tyr_count = cdr_sequence.count('Y')
if tyr_count < 2:
strategies.append({
'strategy': 'Tyrosine enrichment',
'rationale': 'Tyr provides pi-stacking and H-bonds',
'expected_impact': '+2-3x affinity improvement',
'targets': suggest_tyr_positions(cdr_sequence)
})
# Strategy 3: Charged residue optimization
if 'PD' in cdr_sequence or 'EP' in cdr_sequence:
strategies.append({
'strategy': 'Salt bridge formation',
'rationale': 'Add charged residues for electrostatic interactions',
'expected_impact': '+1-2x affinity and pH sensitivity',
'targets': identify_salt_bridge_opportunities(cdr_sequence)
})
return strategiespython
def cdr_optimization_strategies(cdr_sequence, cdr_name):
"""基于序列和结构识别CDR优化策略。"""
strategies = []
# 策略1: 延长CDR以增加接触面积
if len(cdr_sequence) < 12 and cdr_name == 'CDR-H3':
strategies.append({
'strategy': 'CDR-H3延长',
'rationale': '添加1-2个残基以增加结合表面积',
'expected_impact': '+2-5倍亲和力提升',
'examples': ['添加Gly-Tyr', '添加Ser-Asp']
})
# 策略2: 酪氨酸富集
tyr_count = cdr_sequence.count('Y')
if tyr_count < 2:
strategies.append({
'strategy': '酪氨酸富集',
'rationale': '酪氨酸可提供π-堆积和氢键相互作用',
'expected_impact': '+2-3倍亲和力提升',
'targets': suggest_tyr_positions(cdr_sequence)
})
# 策略3: 带电残基优化
if 'PD' in cdr_sequence or 'EP' in cdr_sequence:
strategies.append({
'strategy': '盐桥形成',
'rationale': '添加带电残基以形成静电相互作用',
'expected_impact': '+1-2倍亲和力提升及pH敏感性',
'targets': identify_salt_bridge_opportunities(cdr_sequence)
})
return strategies4.3 Output for Report
4.3 报告输出内容
markdown
undefinedmarkdown
undefined4. Affinity Optimization
4. 亲和力优化
4.1 Current Affinity Assessment
4.1 当前亲和力评估
| Property | Value | Method |
|---|---|---|
| Predicted KD | 5.2 nM | Structure-based prediction |
| Buried surface area | 820 Ų | AlphaFold model |
| Interface hotspots | 6 residues | Energy decomposition |
Target: Single-digit nM affinity (KD < 5 nM)
| 属性 | 数值 | 方法 |
|---|---|---|
| 预测KD值 | 5.2 nM | 基于结构的预测 |
| 掩埋表面积 | 820 Ų | AlphaFold模型 |
| 界面热点残基 | 6个 | 能量分解分析 |
目标: 纳摩尔级亲和力(KD < 5 nM)
4.2 Proposed Affinity Mutations
4.2 建议的亲和力突变
High-Priority Mutations (predicted >2x improvement):
| Position | Original | Mutant | Region | Predicted ΔΔG | KD Fold Improvement | Rationale |
|---|---|---|---|---|---|---|
| H100a | S | Y | CDR-H3 | -1.2 kcal/mol | 7.4x | Pi-stacking with target Phe |
| H52 | I | W | CDR-H2 | -0.9 kcal/mol | 4.8x | Increased hydrophobic contact |
| L91 | Q | E | CDR-L3 | -0.7 kcal/mol | 3.3x | Salt bridge with target Arg |
| H58 | G | S | CDR-H2 | -0.6 kcal/mol | 2.7x | H-bond to target backbone |
Medium-Priority Mutations (predicted 1.5-2x improvement):
| Position | Original | Mutant | Region | Predicted ΔΔG | KD Fold Improvement | Rationale |
|---|---|---|---|---|---|---|
| H33 | Y | F | CDR-H1 | -0.5 kcal/mol | 2.3x | Optimize stacking geometry |
| L50 | A | T | CDR-L2 | -0.4 kcal/mol | 2.0x | Additional H-bond |
高优先级突变(预测提升>2倍):
| 位置 | 原始残基 | 突变残基 | 区域 | 预测ΔΔG | KD值提升倍数 | 依据 |
|---|---|---|---|---|---|---|
| H100a | S | Y | CDR-H3 | -1.2 kcal/mol | 7.4倍 | 与靶点苯丙氨酸形成π-堆积 |
| H52 | I | W | CDR-H2 | -0.9 kcal/mol | 4.8倍 | 增加疏水相互作用 |
| L91 | Q | E | CDR-L3 | -0.7 kcal/mol | 3.3倍 | 与靶点精氨酸形成盐桥 |
| H58 | G | S | CDR-H2 | -0.6 kcal/mol | 2.7倍 | 与靶点主链形成氢键 |
中优先级突变(预测提升1.5-2倍):
| 位置 | 原始残基 | 突变残基 | 区域 | 预测ΔΔG | KD值提升倍数 | 依据 |
|---|---|---|---|---|---|---|
| H33 | Y | F | CDR-H1 | -0.5 kcal/mol | 2.3倍 | 优化堆积几何结构 |
| L50 | A | T | CDR-L2 | -0.4 kcal/mol | 2.0倍 | 增加氢键相互作用 |
4.3 Combination Strategy
4.3 组合策略
Recommended Testing Order:
- Single mutants: H100aY, H52W, L91E (test individually)
- Double mutants: H100aY+H52W, H100aY+L91E (best combinations)
- Triple mutant: H100aY+H52W+L91E (if additivity observed)
Expected Outcome:
- Single mutants: KD 1.5-2.5 nM (3-7x improvement)
- Best double mutant: KD 0.7-1.2 nM (7-15x improvement)
- Triple mutant: KD 0.3-0.6 nM (15-30x improvement) if additive
建议测试顺序:
- 单点突变: H100aY、H52W、L91E(单独测试)
- 双点突变: H100aY+H52W、H100aY+L91E(最优组合)
- 三点突变: H100aY+H52W+L91E(如观察到叠加效应)
预期结果:
- 单点突变: KD值1.5-2.5 nM(3-7倍提升)
- 最优双点突变: KD值0.7-1.2 nM(7-15倍提升)
- 三点突变: 如叠加效应存在,KD值0.3-0.6 nM(15-30倍提升)
4.4 CDR Optimization Strategies
4.4 CDR优化策略
Strategy 1: CDR-H3 Extension
- Current length: 14 aa
- Proposed: Add Gly-Tyr at C-terminus (16 aa total)
- Rationale: Fill gap in binding interface, Tyr provides pi-stacking
- Expected impact: +2-3x affinity
Strategy 2: Tyrosine Enrichment
- Current Tyr count: 3 in CDRs
- Target positions: H33, H52a, L96
- Rationale: Tyr provides both hydrophobic and H-bond contacts
- Expected impact: +2-4x affinity
Strategy 3: pH-Dependent Binding (Optional)
- For tumor-selective uptake
- Add His residues at interface: H100a, L91
- pKa ~6.0: Bind at pH 7.4, release at pH 6.0
- Expected impact: Tumor selectivity, faster recycling
Source: In silico modeling, structural analysis
---策略1: CDR-H3延长
- 当前长度: 14 aa
- 建议: 在C末端添加Gly-Tyr(总长度16 aa)
- 依据: 填补结合界面间隙,酪氨酸提供π-堆积作用
- 预期影响: +2-3倍亲和力提升
策略2: 酪氨酸富集
- 当前CDR区酪氨酸数量: 3个
- 目标位置: H33、H52a、L96
- 依据: 酪氨酸可同时提供疏水和氢键相互作用
- 预期影响: +2-4倍亲和力提升
策略3: pH依赖性结合(可选)
- 用于肿瘤选择性摄取
- 在结合界面添加组氨酸残基: H100a、L91
- pKa ~6.0: 在pH7.4下结合,pH6.0下解离
- 预期影响: 肿瘤选择性,循环半衰期延长
来源: 计算建模, 结构分析
---Phase 5: Developability Assessment
阶段5: 成药性评估
5.1 Aggregation Propensity
5.1 聚集倾向性
python
def assess_aggregation(sequence):
"""Comprehensive aggregation risk assessment."""
# Identify aggregation-prone regions (APR)
aprs = find_aggregation_motifs(sequence)
# Hydrophobic patches on surface
hydrophobic_patches = identify_surface_hydrophobic(sequence)
# Charge patches (extreme pI regions)
charge_patches = identify_charge_clusters(sequence)
# Sequence-based prediction scores
tango_score = predict_tango_score(sequence) # Beta-aggregation
aggrescan_score = predict_aggrescan(sequence) # General aggregation
# Isoelectric point
pi = calculate_isoelectric_point(sequence)
return {
'apr_count': len(aprs),
'apr_regions': aprs,
'hydrophobic_patches': hydrophobic_patches,
'charge_patches': charge_patches,
'tango_score': tango_score,
'aggrescan_score': aggrescan_score,
'pi': pi,
'overall_risk': categorize_risk(tango_score, aggrescan_score, len(aprs))
}python
def assess_aggregation(sequence):
"""综合评估聚集风险。"""
# 识别聚集倾向性区域(APR)
aprs = find_aggregation_motifs(sequence)
# 表面疏水斑块
hydrophobic_patches = identify_surface_hydrophobic(sequence)
# 电荷斑块(极端pI区域)
charge_patches = identify_charge_clusters(sequence)
# 基于序列的预测评分
tango_score = predict_tango_score(sequence) # β-聚集倾向性
aggrescan_score = predict_aggrescan(sequence) # 整体聚集倾向性
# 等电点
pi = calculate_isoelectric_point(sequence)
return {
'apr_count': len(aprs),
'apr_regions': aprs,
'hydrophobic_patches': hydrophobic_patches,
'charge_patches': charge_patches,
'tango_score': tango_score,
'aggrescan_score': aggrescan_score,
'pi': pi,
'overall_risk': categorize_risk(tango_score, aggrescan_score, len(aprs))
}5.2 PTM Site Identification
5.2 PTM位点识别
python
def identify_ptm_sites(sequence):
"""Identify post-translational modification liability sites."""
ptm_sites = {
'deamidation': [],
'isomerization': [],
'oxidation': [],
'glycosylation': []
}
# Deamidation: Asn followed by Gly or Ser (NG, NS motifs)
for i, aa in enumerate(sequence[:-1]):
if aa == 'N' and sequence[i+1] in ['G', 'S']:
ptm_sites['deamidation'].append({
'position': i,
'motif': sequence[i:i+2],
'risk': 'High' if sequence[i+1] == 'G' else 'Medium',
'region': identify_region(i)
})
# Isomerization: Asp followed by Gly or Ser (DG, DS motifs)
for i, aa in enumerate(sequence[:-1]):
if aa == 'D' and sequence[i+1] in ['G', 'S']:
ptm_sites['isomerization'].append({
'position': i,
'motif': sequence[i:i+2],
'risk': 'High',
'region': identify_region(i)
})
# Oxidation: Met and Trp residues
for i, aa in enumerate(sequence):
if aa in ['M', 'W']:
ptm_sites['oxidation'].append({
'position': i,
'residue': aa,
'risk': 'Medium',
'region': identify_region(i)
})
# N-glycosylation: N-X-S/T motif (X != P)
for i in range(len(sequence)-2):
if sequence[i] == 'N' and sequence[i+1] != 'P' and sequence[i+2] in ['S', 'T']:
ptm_sites['glycosylation'].append({
'position': i,
'motif': sequence[i:i+3],
'region': identify_region(i)
})
return ptm_sitespython
def identify_ptm_sites(sequence):
"""识别翻译后修饰(PTM)风险位点。"""
ptm_sites = {
'脱酰胺': [],
'异构化': [],
'氧化': [],
'糖基化': []
}
# 脱酰胺: 天冬酰胺后接甘氨酸或丝氨酸(NG、NS基序)
for i, aa in enumerate(sequence[:-1]):
if aa == 'N' and sequence[i+1] in ['G', 'S']:
ptm_sites['脱酰胺'].append({
'position': i,
'motif': sequence[i:i+2],
'risk': '高' if sequence[i+1] == 'G' else '中',
'region': identify_region(i)
})
# 异构化: 天冬氨酸后接甘氨酸或丝氨酸(DG、DS基序)
for i, aa in enumerate(sequence[:-1]):
if aa == 'D' and sequence[i+1] in ['G', 'S']:
ptm_sites['异构化'].append({
'position': i,
'motif': sequence[i:i+2],
'risk': '高',
'region': identify_region(i)
})
# 氧化: 甲硫氨酸和色氨酸残基
for i, aa in enumerate(sequence):
if aa in ['M', 'W']:
ptm_sites['氧化'].append({
'position': i,
'residue': aa,
'risk': '中',
'region': identify_region(i)
})
# N-糖基化: N-X-S/T基序(X≠P)
for i in range(len(sequence)-2):
if sequence[i] == 'N' and sequence[i+1] != 'P' and sequence[i+2] in ['S', 'T']:
ptm_sites['糖基化'].append({
'position': i,
'motif': sequence[i:i+3],
'region': identify_region(i)
})
return ptm_sites5.3 Developability Scoring
5.3 成药性评分
python
def calculate_developability_score(sequence, structure):
"""Calculate comprehensive developability score (0-100)."""
# Component scores
aggregation = assess_aggregation(sequence)
ptm = identify_ptm_sites(sequence)
stability = predict_thermal_stability(structure)
expression = predict_expression_level(sequence)
solubility = predict_solubility(sequence)
# Scoring rubric (0-100 for each)
scores = {
'aggregation': score_aggregation(aggregation), # 100 = low risk
'ptm_liability': score_ptm_risk(ptm), # 100 = no PTM sites
'stability': score_stability(stability), # 100 = Tm > 70°C
'expression': score_expression(expression), # 100 = >1 g/L
'solubility': score_solubility(solubility) # 100 = >100 mg/mL
}
# Weighted average
weights = {
'aggregation': 0.30, # Most critical
'ptm_liability': 0.25,
'stability': 0.20,
'expression': 0.15,
'solubility': 0.10
}
overall = sum(scores[k] * weights[k] for k in scores.keys())
return {
'component_scores': scores,
'overall_score': overall,
'tier': categorize_developability(overall)
}python
def calculate_developability_score(sequence, structure):
"""计算综合成药性评分(0-100)。"""
# 各维度评分
aggregation = assess_aggregation(sequence)
ptm = identify_ptm_sites(sequence)
stability = predict_thermal_stability(structure)
expression = predict_expression_level(sequence)
solubility = predict_solubility(sequence)
# 评分标准(各维度0-100分)
scores = {
'aggregation': score_aggregation(aggregation), # 100=低风险
'ptm_liability': score_ptm_risk(ptm), # 100=无PTM风险位点
'stability': score_stability(stability), # 100=Tm>70°C
'expression': score_expression(expression), # 100=>1g/L
'solubility': score_solubility(solubility) # 100=>100mg/mL
}
# 加权平均
weights = {
'aggregation': 0.30, # 最关键
'ptm_liability': 0.25,
'stability': 0.20,
'expression': 0.15,
'solubility': 0.10
}
overall = sum(scores[k] * weights[k] for k in scores.keys())
return {
'component_scores': scores,
'overall_score': overall,
'tier': categorize_developability(overall)
}5.4 Output for Report
5.4 报告输出内容
markdown
undefinedmarkdown
undefined5. Developability Assessment
5. 成药性评估
5.1 Overall Developability Score
5.1 综合成药性评分
| Variant | Aggregation | PTM Liability | Stability | Expression | Solubility | Overall | Tier |
|---|---|---|---|---|---|---|---|
| Original (Mouse) | 58 | 45 | 72 | 65 | 70 | 62 | T3 |
| VH_Humanized_v1 | 72 | 55 | 75 | 78 | 75 | 71 | T2 |
| VH_Humanized_v2 | 68 | 58 | 74 | 75 | 73 | 69 | T2 |
| Affinity_opt | 85 | 72 | 78 | 80 | 82 | 79 | T1 |
Scoring: 0-100 scale (higher is better), Tiers: T1 (>75), T2 (60-75), T3 (<60)
| 变体 | 聚集风险 | PTM风险 | 稳定性 | 表达量 | 溶解度 | 综合评分 | 等级 |
|---|---|---|---|---|---|---|---|
| 原始鼠源序列 | 58 | 45 | 72 | 65 | 70 | 62 | T3 |
| VH_Humanized_v1 | 72 | 55 | 75 | 78 | 75 | 71 | T2 |
| VH_Humanized_v2 | 68 | 58 | 74 | 75 | 73 | 69 | T2 |
| 亲和力优化变体 | 85 | 72 | 78 | 80 | 82 | 79 | T1 |
评分标准: 0-100分(越高越好),等级划分: T1(>75), T2(60-75), T3(<60)
5.2 Aggregation Analysis
5.2 聚集分析
Aggregation-Prone Regions (APR) in VH:
| Position | Sequence | Region | TANGO Score | Risk | Recommendation |
|---|---|---|---|---|---|
| 85-92 | STSTAYMEL | FR3 | 42 | Medium | Consider T86S mutation |
| 108-112 | DDGSY | CDR-H3 | 28 | Low | Monitor in formulation |
Overall Aggregation Risk:
- VH: Low (TANGO: 15, AGGRESCAN: -12)
- VL: Very Low (TANGO: 8, AGGRESCAN: -18)
- pI: VH 7.2, VL 5.8 (favorable for purification)
Recommendations:
- Formulate at pH 6.0-6.5 (below pI of VH)
- Add arginine-glutamate (20-50 mM) to reduce aggregation
- Target concentration: >100 mg/mL achievable
VH链中的聚集倾向性区域(APR):
| 位置 | 序列 | 区域 | TANGO评分 | 风险 | 建议 |
|---|---|---|---|---|---|
| 85-92 | STSTAYMEL | FR3 | 42 | 中 | 考虑T86S突变 |
| 108-112 | DDGSY | CDR-H3 | 28 | 低 | 制剂中监测 |
整体聚集风险:
- VH链: 低(TANGO:15, AGGRESCAN:-12)
- VL链: 极低(TANGO:8, AGGRESCAN:-18)
- pI: VH7.2, VL5.8(利于纯化)
建议:
- 在pH6.0-6.5条件下制剂(低于VH链pI)
- 添加20-50 mM精氨酸-谷氨酸以减少聚集
- 可实现>100 mg/mL的目标浓度
5.3 PTM Liability Sites
5.3 PTM风险位点
High-Risk PTM Sites (require mitigation):
| Position | Motif | PTM Type | Risk | Region | Mitigation Strategy |
|---|---|---|---|---|---|
| H54-55 | NG | Deamidation | High | CDR-H2 | Mutate to NQ or QG |
| H84-85 | DS | Isomerization | High | FR3 | Mutate to ES or DA |
| L28 | M | Oxidation | Medium | CDR-L1 | Mutate to Leu or Ile |
Medium-Risk Sites:
- H89: Trp (oxidation) - Monitor but likely stable in framework
- L97: Asn (deamidation, NS motif) - Low risk in CDR-L3
Mitigation Priority:
- H54-55 (NG → NQ): Removes high-risk deamidation, retains H-bond capability
- H84-85 (DS → ES): Removes isomerization, maintains charge
- L28 (M → L): Reduces oxidation risk, maintains hydrophobicity
Expected Impact: Mitigation improves PTM score from 72 → 92
高风险PTM位点(需缓解):
| 位置 | 基序 | PTM类型 | 风险 | 区域 | 缓解策略 |
|---|---|---|---|---|---|
| H54-55 | NG | 脱酰胺 | 高 | CDR-H2 | 突变为NQ或QG |
| H84-85 | DS | 异构化 | 高 | FR3 | 突变为ES或DA |
| L28 | M | 氧化 | 中 | CDR-L1 | 突变为亮氨酸或异亮氨酸 |
中风险位点:
- H89: 色氨酸(氧化)- 监测即可,框架区中通常稳定
- L97: 天冬酰胺(脱酰胺,NS基序)- CDR-L3中风险较低
缓解优先级:
- H54-55(NG→NQ): 消除高风险脱酰胺位点,保留氢键能力
- H84-85(DS→ES): 消除异构化风险,维持电荷
- L28(M→L): 降低氧化风险,维持疏水性
预期影响: 缓解后PTM评分从72提升至92
5.4 Stability Predictions
5.4 稳定性预测
Thermal Stability:
| Variant | Predicted Tm (°C) | ΔTm vs Original | Aggregation Tonset | Stability Tier |
|---|---|---|---|---|
| Original | 68 | - | 62°C | T3 (Marginal) |
| Humanized_v2 | 71 | +3°C | 64°C | T2 (Good) |
| Affinity_opt | 73 | +5°C | 67°C | T2 (Good) |
| PTM_mitigated | 74 | +6°C | 69°C | T1 (Excellent) |
Target: Tm >70°C, Tonset >65°C for long-term stability
Stability Optimization:
- Framework humanization improved Tm by +3°C
- Removal of destabilizing motifs: +2°C
- Further optimization possible: Proline introduction in loops
热稳定性:
| 变体 | 预测Tm(°C) | 与原始序列的ΔTm | 聚集起始温度 | 稳定性等级 |
|---|---|---|---|---|
| 原始序列 | 68 | - | 62°C | T3(边缘水平) |
| 人源化v2 | 71 | +3°C | 64°C | T2(良好) |
| 亲和力优化变体 | 73 | +5°C | 67°C | T2(良好) |
| PTM缓解后变体 | 74 | +6°C | 69°C | T1(优秀) |
目标: Tm>70°C,聚集起始温度>65°C以保证长期稳定性
稳定性优化:
- 框架区人源化使Tm提升+3°C
- 去除不稳定基序使Tm提升+2°C
- 进一步优化方向: 在环区引入脯氨酸
5.5 Expression & Manufacturing
5.5 表达与生产
Expression Prediction (CHO cells):
| Variant | Predicted Titer (g/L) | Soluble Fraction | His-tag Purification | Overall |
|---|---|---|---|---|
| Original | 1.2 | 75% | Good | T2 |
| Humanized_v2 | 1.8 | 85% | Excellent | T1 |
| Affinity_opt | 2.1 | 88% | Excellent | T1 |
Manufacturing Considerations:
- No unusual codons → Good for CHO expression
- No free cysteines → No misfolding risk
- Neutral pI → Easy purification by ion exchange
- Low aggregation → High formulation concentration possible
Predicted Manufacturing Profile:
- Expression: 2.0 g/L (CHO fed-batch)
- Purification yield: 75-80%
- Final formulation: >150 mg/mL achievable
- Shelf life: >2 years at 4°C (estimated)
Source: In silico predictions, sequence analysis
---表达预测(CHO细胞):
| 变体 | 预测滴度(g/L) | 可溶性比例 | Protein A纯化效果 | 综合等级 |
|---|---|---|---|---|
| 原始序列 | 1.2 | 75% | 良好 | T2 |
| 人源化v2 | 1.8 | 85% | 优秀 | T1 |
| 亲和力优化变体 | 2.1 | 88% | 优秀 | T1 |
生产考量:
- 无稀有密码子 → 适合CHO表达
- 无游离半胱氨酸 → 无错误折叠风险
- 中性pI → 易于通过离子交换纯化
- 低聚集性 → 可实现高制剂浓度
预测生产概况:
- 表达量: 2.0 g/L(CHO流加培养)
- 纯化收率: 75-80%
- 最终制剂浓度: 可实现>150 mg/mL
- 保质期: 4°C下>2年(预估)
来源: 计算预测, 序列分析
---Phase 6: Immunogenicity Prediction
阶段6: 免疫原性预测
6.1 T-Cell Epitope Prediction
6.1 T细胞表位预测
python
def predict_tcell_epitopes(tu, sequence):
"""Predict T-cell epitopes using IEDB tools."""
# MHC-II binding prediction (immunogenicity risk)
# Query IEDB for predicted epitopes
predicted_epitopes = []
# Scan sequence with 9-mer sliding window
for i in range(len(sequence) - 8):
peptide = sequence[i:i+9]
# Search IEDB for similar epitopes
iedb_results = tu.tools.iedb_search_epitopes(
sequence_contains=peptide[:5], # Core sequence
limit=10
)
# If found in IEDB → higher risk
if len(iedb_results) > 0:
predicted_epitopes.append({
'position': i,
'peptide': peptide,
'risk': 'High',
'evidence': f"{len(iedb_results)} similar epitopes in IEDB"
})
# Score overall immunogenicity risk
risk_score = calculate_immunogenicity_risk(predicted_epitopes, sequence)
return {
'epitope_count': len(predicted_epitopes),
'high_risk_epitopes': [e for e in predicted_epitopes if e['risk'] == 'High'],
'risk_score': risk_score,
'recommendation': recommend_deimmunization(predicted_epitopes)
}python
def predict_tcell_epitopes(tu, sequence):
"""利用IEDB工具预测T细胞表位。"""
# MHC-II结合预测(免疫原性风险)
# 查询IEDB获取预测表位
predicted_epitopes = []
# 用9肽滑动窗口扫描序列
for i in range(len(sequence) - 8):
peptide = sequence[i:i+9]
# 在IEDB中搜索相似表位
iedb_results = tu.tools.iedb_search_epitopes(
sequence_contains=peptide[:5], # 核心序列
limit=10
)
# 如果在IEDB中存在 → 风险更高
if len(iedb_results) > 0:
predicted_epitopes.append({
'position': i,
'peptide': peptide,
'risk': '高',
'evidence': f"IEDB中存在{len(iedb_results)}个相似表位"
})
# 计算整体免疫原性风险评分
risk_score = calculate_immunogenicity_risk(predicted_epitopes, sequence)
return {
'epitope_count': len(predicted_epitopes),
'high_risk_epitopes': [e for e in predicted_epitopes if e['risk'] == '高'],
'risk_score': risk_score,
'recommendation': recommend_deimmunization(predicted_epitopes)
}6.2 Immunogenicity Risk Scoring
6.2 免疫原性风险评分
python
def calculate_immunogenicity_risk(epitopes, sequence):
"""Calculate comprehensive immunogenicity risk score."""
# Component 1: T-cell epitope count (IEDB-based)
tcell_score = len(epitopes) * 10 # Each epitope adds 10 points
# Component 2: Non-human residues in framework
non_human_residues = count_non_human_residues(sequence)
non_human_score = non_human_residues * 5
# Component 3: Aggregation-related immunogenicity
aggregation_score = assess_aggregation(sequence)['overall_risk'] * 20
# Total risk (0-100, lower is better)
total_risk = min(100, tcell_score + non_human_score + aggregation_score)
return {
'tcell_risk': tcell_score,
'non_human_risk': non_human_score,
'aggregation_risk': aggregation_score,
'total_risk': total_risk,
'category': 'Low' if total_risk < 30 else 'Medium' if total_risk < 60 else 'High'
}python
def calculate_immunogenicity_risk(epitopes, sequence):
"""计算综合免疫原性风险评分。"""
# 维度1: T细胞表位数量(基于IEDB)
tcell_score = len(epitopes) * 10 # 每个表位加10分
# 维度2: 框架区中的非人源残基数量
non_human_residues = count_non_human_residues(sequence)
non_human_score = non_human_residues * 5
# 维度3: 聚集相关免疫原性
aggregation_score = assess_aggregation(sequence)['overall_risk'] * 20
# 总风险(0-100,越低越好)
total_risk = min(100, tcell_score + non_human_score + aggregation_score)
return {
'tcell_risk': tcell_score,
'non_human_risk': non_human_score,
'aggregation_risk': aggregation_score,
'total_risk': total_risk,
'category': '低' if total_risk < 30 else '中' if total_risk < 60 else '高'
}6.3 Output for Report
6.3 报告输出内容
markdown
undefinedmarkdown
undefined6. Immunogenicity Prediction
6. 免疫原性预测
6.1 T-Cell Epitope Analysis
6.1 T细胞表位分析
Predicted MHC-II Binding Epitopes (IEDB):
| Position | Peptide | MHC Alleles | IEDB Matches | Risk Level | Region |
|---|---|---|---|---|---|
| VH 48-56 | QGLEWMGGI | HLA-DR1, DR4 | 3 | Medium | FR2 |
| VH 78-86 | TDTSTSTA | HLA-DR1 | 5 | High | FR3 (mouse residues) |
| VL 52-60 | LLIYSASSL | HLA-DR1, DR15 | 2 | Medium | FR2 |
High-Risk Epitope Details:
- VH 78-86 (TDTSTSTA): Contains mouse-derived residues T84, S85
- Found in 5 immunogenic peptides in IEDB
- Recommendation: Backmutate to human consensus (TSTSSAYL)
预测的MHC-II结合表位(IEDB):
| 位置 | 肽段 | MHC等位基因 | IEDB匹配数 | 风险等级 | 区域 |
|---|---|---|---|---|---|
| VH48-56 | QGLEWMGGI | HLA-DR1、DR4 | 3 | 中 | FR2 |
| VH78-86 | TDTSTSTA | HLA-DR1 | 5 | 高 | FR3(鼠源残基) |
| VL52-60 | LLIYSASSL | HLA-DR1、DR15 | 2 | 中 | FR2 |
高风险表位详情:
- VH78-86(TDTSTSTA): 包含鼠源残基T84、S85
- 在IEDB中存在5个免疫原性相似肽段
- 建议: 回复突变为人类共识序列(TSTSSAYL)
6.2 Immunogenicity Risk Score
6.2 免疫原性风险评分
| Variant | T-Cell Epitopes | Non-Human Residues | Aggregation Risk | Total Risk | Category |
|---|---|---|---|---|---|
| Original (Mouse) | 12 | 38 | High (40) | 118 | High |
| VH_Humanized_v1 | 5 | 13 | Medium (20) | 60 | Medium |
| VH_Humanized_v2 | 4 | 15 | Medium (18) | 53 | Medium |
| Deimmunized | 2 | 10 | Low (12) | 32 | Low |
Risk Scoring: 0-100 (lower is better)
- Low risk: <30 (clinical candidate ready)
- Medium risk: 30-60 (acceptable with monitoring)
- High risk: >60 (requires optimization)
| 变体 | T细胞表位数量 | 非人源残基数量 | 聚集风险 | 总风险评分 | 类别 |
|---|---|---|---|---|---|
| 原始鼠源序列 | 12 | 38 | 高(40) | 118 | 高 |
| VH_Humanized_v1 | 5 | 13 | 中(20) | 60 | 中 |
| VH_Humanized_v2 | 4 | 15 | 中(18) | 53 | 中 |
| 去免疫原化变体 | 2 | 10 | 低(12) | 32 | 低 |
风险评分标准: 0-100分(越低越好)
- 低风险: <30(可作为临床候选药物)
- 中风险: 30-60(可接受,需监测)
- 高风险: >60(需优化)
6.3 Deimmunization Strategy
6.3 去免疫原化策略
Recommended Mutations (to achieve low risk):
| Position | Original | Mutant | Region | Rationale | Impact |
|---|---|---|---|---|---|
| VH 78 | T | A | FR3 | Human consensus, removes epitope | -15 risk |
| VH 84 | T | S | FR3 | Human consensus, removes epitope | -12 risk |
| VL 55 | S | A | FR2 | Removes MHC-II binding | -8 risk |
Expected Outcome:
- Deimmunization reduces risk score: 53 → 32 (Low)
- T-cell epitopes reduced: 4 → 2
- Maintains CDR sequences (no affinity impact)
建议突变(实现低风险):
| 位置 | 原始残基 | 突变残基 | 区域 | 依据 | 影响 |
|---|---|---|---|---|---|
| VH78 | T | A | FR3 | 人类共识序列,消除表位 | 风险降低15分 |
| VH84 | T | S | FR3 | 人类共识序列,消除表位 | 风险降低12分 |
| VL55 | S | A | FR2 | 消除MHC-II结合 | 风险降低8分 |
预期结果:
- 去免疫原化使风险评分从53降至32(低风险)
- T细胞表位数量从4个降至2个
- 保留CDR序列(无亲和力损失)
6.4 Clinical Precedent Comparison
6.4 临床先例对比
Approved Antibodies - Immunogenicity Rates:
| Antibody | Target | % ADA (Anti-Drug Antibodies) | Humanization |
|---|---|---|---|
| Atezolizumab | PD-L1 | 30% | Fully human |
| Durvalumab | PD-L1 | 6% | Fully human |
| Trastuzumab | HER2 | 13% | Humanized (93%) |
| Rituximab | CD20 | 11% | Chimeric (66%) |
Our Candidate:
- Humanization: 85-87% (similar to trastuzumab)
- Predicted ADA risk: 10-15% (after deimmunization)
- Acceptable for clinical development
Source: IEDB, TheraSAbDab, clinical trial data
---已获批抗体的免疫原性发生率:
| 抗体 | 靶点 | %ADA(抗药物抗体) | 人源化程度 |
|---|---|---|---|
| Atezolizumab | PD-L1 | 30% | 全人源 |
| Durvalumab | PD-L1 | 6% | 全人源 |
| Trastuzumab | HER2 | 13% | 人源化(93%) |
| Rituximab | CD20 | 11% | 嵌合型(66%) |
候选抗体:
- 人源化程度: 85-87%(与Trastuzumab相似)
- 预测ADA风险: 10-15%(去免疫原化后)
- 符合临床开发要求
来源: IEDB, TheraSAbDab, 临床试验数据
---Phase 7: Manufacturing Feasibility
阶段7: 生产可行性分析
7.1 Expression Optimization
7.1 表达优化
python
def assess_manufacturing_feasibility(sequence):
"""Assess manufacturing and CMC feasibility."""
# Codon optimization for CHO
cho_optimized = optimize_codons(sequence, host='CHO')
rare_codons = count_rare_codons(sequence, host='CHO')
# Signal peptide design
signal_peptide = design_signal_peptide(sequence)
# Purification considerations
purification = {
'protein_a_binding': check_protein_a_binding(sequence),
'ion_exchange': suggest_ion_exchange_conditions(sequence),
'hydrophobic': suggest_hic_conditions(sequence)
}
# Formulation
formulation = {
'target_concentration': predict_max_concentration(sequence),
'buffer': suggest_buffer_conditions(sequence),
'stabilizers': suggest_stabilizers(sequence),
'shelf_life': predict_shelf_life(sequence)
}
return {
'expression': {'cho_optimized': cho_optimized, 'rare_codons': rare_codons},
'purification': purification,
'formulation': formulation
}python
def assess_manufacturing_feasibility(sequence):
"""评估生产及CMC可行性。"""
# CHO细胞密码子优化
cho_optimized = optimize_codons(sequence, host='CHO')
rare_codons = count_rare_codons(sequence, host='CHO')
# 信号肽设计
signal_peptide = design_signal_peptide(sequence)
# 纯化考量
purification = {
'protein_a_binding': check_protein_a_binding(sequence),
'ion_exchange': suggest_ion_exchange_conditions(sequence),
'hydrophobic': suggest_hic_conditions(sequence)
}
# 制剂
formulation = {
'target_concentration': predict_max_concentration(sequence),
'buffer': suggest_buffer_conditions(sequence),
'stabilizers': suggest_stabilizers(sequence),
'shelf_life': predict_shelf_life(sequence)
}
return {
'expression': {'cho_optimized': cho_optimized, 'rare_codons': rare_codons},
'purification': purification,
'formulation': formulation
}7.2 Output for Report
7.2 报告输出内容
markdown
undefinedmarkdown
undefined7. Manufacturing Feasibility
7. 生产可行性分析
7.1 Expression Assessment
7.1 表达评估
Expression System: CHO (Chinese Hamster Ovary) cells
| Parameter | Assessment | Details |
|---|---|---|
| Codon optimization | Good | 5% rare codons (CHO) |
| Signal peptide | Native IgG leader | METDTLLLWVLLLWVPGSTG |
| Predicted titer | 2.0 g/L | Fed-batch, 14-day culture |
| Soluble fraction | 88% | High solubility predicted |
Recommendations:
- Use standard CHO expression system (CHO-K1 or CHO-S)
- Express as full IgG1 (not Fab) for Protein A purification
- Standard fed-batch process (no special requirements)
表达系统: CHO(中国仓鼠卵巢)细胞
| 参数 | 评估结果 | 详情 |
|---|---|---|
| 密码子优化 | 良好 | CHO细胞中稀有密码子占比5% |
| 信号肽 | 天然IgG前导肽 | METDTLLLWVLLLWVPGSTG |
| 预测滴度 | 2.0 g/L | 流加培养,14天周期 |
| 可溶性比例 | 88% | 预测溶解度高 |
建议:
- 使用标准CHO表达系统(CHO-K1或CHO-S)
- 表达为完整IgG1(而非Fab)以利用Protein A纯化
- 采用标准流加培养工艺(无特殊要求)
7.2 Purification Strategy
7.2 纯化策略
Recommended 3-Step Purification:
| Step | Method | Purpose | Expected Yield | Purity |
|---|---|---|---|---|
| 1. Capture | Protein A affinity | IgG capture | >95% | >90% |
| 2. Polishing | Cation exchange (SP) | Aggregate/variant removal | >90% | >98% |
| 3. Viral | Nanofiltration (20 nm) | Viral clearance | >95% | >99% |
Overall Process Yield: 75-80% (from clarified harvest to final product)
Purification Conditions:
- Protein A: Standard pH 3.5 elution
- Cation exchange: pH 5.0-5.5 binding, salt gradient elution
- No special requirements (standard IgG process)
建议三步纯化流程:
| 步骤 | 方法 | 目的 | 预期收率 | 纯度 |
|---|---|---|---|---|
| 1. 捕获 | Protein A亲和层析 | IgG捕获 | >95% | >90% |
| 2. 精纯 | 阳离子交换(SP) | 去除聚集体/变体 | >90% | >98% |
| 3. 病毒去除 | 纳米过滤(20 nm) | 病毒清除 | >95% | >99% |
整体工艺收率: 75-80%(从澄清收获液到最终产品)
纯化条件:
- Protein A: 标准pH3.5洗脱
- 阳离子交换: pH5.0-5.5结合,盐梯度洗脱
- 无特殊要求(标准IgG工艺)
7.3 Formulation Development
7.3 制剂开发
Recommended Formulation:
| Component | Concentration | Purpose |
|---|---|---|
| Antibody | 150 mg/mL | High concentration for SC delivery |
| Buffer | 20 mM Histidine-HCl | pH buffering, stability |
| pH | 6.0 | Minimizes aggregation (below pI) |
| Stabilizer | 0.02% Polysorbate 80 | Reduces surface adsorption |
| Tonicity | 240 mM Sucrose | Isotonic, cryoprotectant |
Formulation Characteristics:
- Viscosity: <15 cP (suitable for SC injection)
- Osmolality: 300 mOsm/kg (isotonic)
- Stability: >2 years at 2-8°C (predicted)
- Freeze/thaw: Stable for 5 cycles
Alternative Formulations (if needed):
- Lower concentration (100 mg/mL) for IV delivery
- Add arginine-glutamate (50 mM) if aggregation observed
- Trehalose (5%) as alternative stabilizer
建议制剂配方:
| 组分 | 浓度 | 用途 |
|---|---|---|
| 抗体 | 150 mg/mL | 高浓度用于皮下注射 |
| 缓冲液 | 20 mM组氨酸-HCl | pH缓冲,维持稳定性 |
| pH值 | 6.0 | 最小化聚集(低于pI) |
| 稳定剂 | 0.02%聚山梨酯80 | 减少表面吸附 |
| 渗透压调节剂 | 240 mM蔗糖 | 等渗,冷冻保护剂 |
制剂特性:
- 粘度: <15 cP(适合皮下注射)
- 渗透压: 300 mOsm/kg(等渗)
- 稳定性: 2-8°C下>2年(预测)
- 冻融稳定性: 可耐受5次冻融循环
备选制剂(如需):
- 低浓度(100 mg/mL)用于静脉注射
- 若出现聚集,添加50 mM精氨酸-谷氨酸
- 以5%海藻糖作为备选稳定剂
7.4 Analytical Characterization
7.4 分析表征
Required Assays (ICH guidelines):
| Assay | Purpose | Specification |
|---|---|---|
| SEC-MALS | Monomer content | >95% monomer |
| CEX | Charge variants | Main peak >70% |
| CE-SDS | Purity (reduced/non-reduced) | >95% main peak |
| IEF/cIEF | Isoelectric point | pI 7.0-7.5 |
| SPR/ELISA | Binding affinity | KD <5 nM |
| DSF | Thermal stability | Tm >65°C |
| Cell-based | Bioactivity | EC50 <10 nM |
必需检测项目(ICH指南):
| 检测项目 | 目的 | 质量标准 |
|---|---|---|
| SEC-MALS | 单体含量 | >95%单体 |
| CEX | 电荷变体 | 主峰占比>70% |
| CE-SDS | 纯度(还原/非还原) | 主峰占比>95% |
| IEF/cIEF | 等电点 | pI7.0-7.5 |
| SPR/ELISA | 结合亲和力 | KD<5 nM |
| DSF | 热稳定性 | Tm>65°C |
| 细胞水平检测 | 生物活性 | EC50<10 nM |
7.5 CMC Timeline & Costs
7.5 CMC timeline & Costs
Estimated Development Timeline:
| Phase | Duration | Activities | Cost Estimate |
|---|---|---|---|
| Cell line development | 4-6 months | Transfection, selection, cloning | $150K |
| Process development | 6-9 months | Optimization, scale-up | $300K |
| Analytical development | 3-6 months | Method development, validation | $200K |
| GMP manufacturing | 9-12 months | Tech transfer, clinical batches | $1-2M |
| Total to IND | 18-24 months | - | $1.65-2.65M |
Manufacturing Scale:
- Phase 1: 5-10g (small scale, 50L bioreactor)
- Phase 2: 50-100g (pilot scale, 200L)
- Phase 3: 500g-1kg (commercial scale, 2000L)
预估开发周期:
| 阶段 | 时长 | 活动 | 成本预估 |
|---|---|---|---|
| 细胞株开发 | 4-6个月 | 转染、筛选、克隆 | $150K |
| 工艺开发 | 6-9个月 | 优化、放大 | $300K |
| 分析方法开发 | 3-6个月 | 方法开发、验证 | $200K |
| GMP生产 | 9-12个月 | 技术转移、临床批次生产 | $1-2M |
| IND申报前总时长 | 18-24个月 | - | $1.65-2.65M |
生产规模:
- I期临床: 5-10g(小试规模,50L生物反应器)
- II期临床: 50-100g(中试规模,200L)
- III期临床: 500g-1kg(商业化规模,2000L)
7.6 Risk Assessment
7.6 风险评估
Manufacturing Risks:
| Risk | Probability | Impact | Mitigation |
|---|---|---|---|
| Low expression | Low | Medium | Codon optimization, promoter engineering |
| Aggregation | Low | High | Optimized formulation, process controls |
| Glycosylation heterogeneity | Medium | Low | CHO cell line selection, process optimization |
| Charge variants | Medium | Low | Process pH control, storage conditions |
Overall Manufacturing Risk: Low (standard IgG process)
Source: CMC assessment, manufacturing predictions
---生产风险:
| 风险 | 概率 | 影响 | 缓解措施 |
|---|---|---|---|
| 低表达量 | 低 | 中 | 密码子优化、启动子工程 |
| 聚集 | 低 | 高 | 优化制剂配方、工艺控制 |
| 糖基化异质性 | 中 | 低 | CHO细胞株选择、工艺优化 |
| 电荷变体 | 中 | 低 | 工艺pH控制、储存条件优化 |
整体生产风险: 低(标准IgG生产工艺)
来源: CMC评估, 生产预测
---Phase 8: Final Report & Recommendations
阶段8: 最终报告与建议
Report Template
报告模板
markdown
undefinedmarkdown
undefinedAntibody Optimization Report: [ANTIBODY_NAME]
抗体优化报告: [抗体名称]
Generated: [Date] | Target: [Target Antigen] | Status: Complete
生成日期: [日期] | 靶点: [靶点抗原] | 状态: 完成
Executive Summary
执行摘要
[Summary of optimization strategy, key improvements, and recommendations...]
Top Candidate: [Variant name]
- Humanization: 87% (from 62%)
- Affinity: 1.2 nM (7x improvement)
- Developability score: 82/100 (Tier 1)
- Immunogenicity: Low risk
- Manufacturing: Standard process
Recommendation: Advance to preclinical development
[优化策略、关键改进及建议摘要...]
最优候选变体: [变体名称]
- 人源化程度: 87%(从62%提升)
- 亲和力: 1.2 nM(提升7倍)
- 成药性评分: 82/100(T1级)
- 免疫原性: 低风险
- 生产: 标准工艺
建议: 推进至临床前开发阶段
1. Input Characterization
1. 输入特征表征
[Section from Phase 1...]
[阶段1内容...]
2. Humanization Strategy
2. 人源化策略
[Section from Phase 2...]
[阶段2内容...]
3. Structure Modeling & Analysis
3. 结构建模与分析
[Section from Phase 3...]
[阶段3内容...]
4. Affinity Optimization
4. 亲和力优化
[Section from Phase 4...]
[阶段4内容...]
5. Developability Assessment
5. 成药性评估
[Section from Phase 5...]
[阶段5内容...]
6. Immunogenicity Prediction
6. 免疫原性预测
[Section from Phase 6...]
[阶段6内容...]
7. Manufacturing Feasibility
7. 生产可行性分析
[Section from Phase 7...]
[阶段7内容...]
8. Final Recommendations
8. 最终建议
8.1 Recommended Candidate
8.1 推荐候选变体
Variant: VH_Humanized_Affinity_Optimized_v3
Sequence:
>VH_v3 | Humanized 87%, Affinity optimized, Deimmunized
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMWGIIPIFGTANY
AQKFQGRVTMTTDTSTSSAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS
>VL_v3 | Humanized 90%
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK变体: VH_Humanized_Affinity_Optimized_v3
序列:
>VH_v3 | 人源化87%, 亲和力优化, 去免疫原化
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMWGIIPIFGTANY
AQKFQGRVTMTTDTSTSSAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS
>VL_v3 | 人源化90%
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK8.2 Key Improvements
8.2 关键改进
| Metric | Original | Optimized | Improvement |
|---|---|---|---|
| Humanness | 62% | 87% | +40% |
| Affinity (KD) | 5.2 nM | 0.8 nM | 6.5x |
| Developability | 62/100 | 82/100 | +32% |
| Immunogenicity risk | High | Low | -70% |
| Stability (Tm) | 68°C | 74°C | +6°C |
| Expression | 1.2 g/L | 2.0 g/L | +67% |
| 指标 | 原始序列 | 优化后序列 | 提升幅度 |
|---|---|---|---|
| 人源化程度 | 62% | 87% | +40% |
| 亲和力(KD) | 5.2 nM | 0.8 nM | 6.5倍 |
| 成药性评分 | 62/100 | 82/100 | +32% |
| 免疫原性风险 | 高 | 低 | -70% |
| 稳定性(Tm) | 68°C | 74°C | +6°C |
| 表达量 | 1.2 g/L | 2.0 g/L | +67% |
8.3 Experimental Validation Plan
8.3 实验验证方案
Phase 1: In Vitro Characterization (3-4 months)
| Assay | Purpose | Timeline |
|---|---|---|
| Affinity (SPR/BLI) | Confirm KD | Week 1-2 |
| Cell-based binding | Target engagement | Week 2-3 |
| Thermal stability (DSF) | Tm measurement | Week 3 |
| Aggregation (SEC) | Monomer content | Week 3-4 |
| Expression (CHO) | Titer confirmation | Week 4-8 |
| Immunogenicity (in silico + PBMC) | ADA prediction | Week 8-12 |
Phase 2: Lead Optimization (2-3 months)
- Test backup variants if needed
- Formulation development
- Scale-up to 100mg
Phase 3: Preclinical Studies (6-12 months)
- In vivo efficacy (tumor models)
- PK/PD studies
- Toxicology (GLP)
阶段1: 体外表征(3-4个月)
| 检测项目 | 目的 | timeline |
|---|---|---|
| 亲和力(SPR/BLI) | 验证KD值 | 第1-2周 |
| 细胞水平结合实验 | 靶点结合验证 | 第2-3周 |
| 热稳定性(DSF) | Tm值测定 | 第3周 |
| 聚集分析(SEC) | 单体含量 | 第3-4周 |
| CHO表达验证 | 滴度确认 | 第4-8周 |
| 免疫原性预测(计算+PBMC) | ADA风险预测 | 第8-12周 |
阶段2: 先导优化(2-3个月)
- 如需,测试备选变体
- 制剂开发
- 放大至100mg级
阶段3: 临床前研究(6-12个月)
- 体内药效(肿瘤模型)
- PK/PD研究
- 毒理学研究(GLP)
8.4 Alternative Variants (Backup)
8.4 备选变体(备份)
| Variant | Profile | Recommendation |
|---|---|---|
| VH_v2 | Higher humanness (90%) but lower affinity (1.8 nM) | Backup if immunogenicity issues |
| VH_v4 | Highest affinity (0.5 nM) but lower developability (72/100) | Research tool only |
| VH_v1 | Balanced (affinity 2.1 nM, dev 78/100) | Second backup |
| 变体 | 特性 | 建议 |
|---|---|---|
| VH_v2 | 人源化程度更高(90%)但亲和力较低(1.8 nM) | 若出现免疫原性问题则作为备份 |
| VH_v4 | 亲和力最高(0.5 nM)但成药性较低(72/100) | 仅作为研究工具 |
| VH_v1 | 性能均衡(亲和力2.1 nM, 成药性78/100) | 第二备份 |
8.5 Intellectual Property Considerations
8.5 知识产权考量
FTO Analysis Required:
- Check existing patents on anti-[target] antibodies
- CDR sequence novelty assessment
- Humanization method IP landscape
Patentability:
- Novel CDR-H3 sequence (14 aa, unique)
- Specific humanization with affinity improvement
- Combination of mutations (H100aY+H52W+L91E)
必需的FTO分析:
- 检索针对[靶点]的现有抗体专利
- CDR序列新颖性评估
- 人源化方法的知识产权格局分析
可专利性:
- 独特的CDR-H3序列(14 aa)
- 特定的人源化+亲和力提升策略
- 组合突变(H100aY+H52W+L91E)
8.6 Next Steps
8.6 下一步计划
Immediate (Month 1-3):
- Synthesize genes for VH_v3, VL_v3, and 2 backups
- Express in CHO cells (transient and stable)
- Purify and characterize (affinity, stability, aggregation)
- Confirm developability predictions
Short-term (Month 4-6):
- Develop stable CHO cell line (top candidate)
- Scale up to 500mg for in vivo studies
- Formulation development and stability studies
- Initiate in vivo efficacy studies
Long-term (Month 7-24):
- GMP manufacturing readiness
- IND-enabling studies (tox, CMC)
- File IND
- Phase 1 clinical trial
短期(第1-3个月):
- 合成VH_v3、VL_v3及2个备份变体的基因
- 在CHO细胞中表达(瞬时+稳定转染)
- 纯化并表征(亲和力、稳定性、聚集性)
- 验证成药性预测结果
中期(第4-6个月):
- 开发候选变体的稳定CHO细胞株
- 放大至500mg级用于体内研究
- 制剂开发及稳定性研究
- 启动体内药效研究
长期(第7-24个月):
- GMP生产准备
- IND申报研究(毒理、CMC)
- 提交IND申请
- I期临床试验
9. Data Sources & Tools Used
9. 数据来源与工具
| Tool | Purpose | Queries |
|---|---|---|
| IMGT | Germline identification | IGHV, IGKV genes |
| TheraSAbDab | Clinical precedents | Anti-[target] antibodies |
| AlphaFold | Structure prediction | VH-VL complex |
| IEDB | Immunogenicity | Epitope prediction |
| SAbDab | Structural analysis | PDB structures |
| UniProt | Target information | [Target accession] |
---| 工具 | 用途 | 查询内容 |
|---|---|---|
| IMGT | 种系基因识别 | IGHV、IGKV等基因 |
| TheraSAbDab | 临床先例查询 | 抗[靶点]抗体 |
| AlphaFold | 结构预测 | VH-VL复合物 |
| IEDB | 免疫原性预测 | 表位预测 |
| SAbDab | 结构分析 | PDB结构 |
| UniProt | 靶点信息获取 | [靶点编号] |
---Evidence Grading System
证据分级体系
| Tier | Symbol | Criteria |
|---|---|---|
| T1 | ★★★ | Humanness >85%, KD <2 nM, Developability >75, Low immunogenicity |
| T2 | ★★☆ | Humanness 70-85%, KD 2-10 nM, Developability 60-75, Medium immunogenicity |
| T3 | ★☆☆ | Humanness <70%, KD >10 nM, Developability <60, or High immunogenicity |
| T4 | ☆☆☆ | Failed validation or major liabilities |
| 等级 | 符号 | 标准 |
|---|---|---|
| T1 | ★★★ | 人源化程度>85%, KD<2 nM, 成药性评分>75, 低免疫原性 |
| T2 | ★★☆ | 人源化程度70-85%, KD2-10 nM, 成药性评分60-75, 中免疫原性 |
| T3 | ★☆☆ | 人源化程度<70%, KD>10 nM, 成药性评分<60, 或高免疫原性 |
| T4 | ☆☆☆ | 验证失败或存在重大缺陷 |
Completeness Checklist
完整性检查清单
Phase 1: Input Analysis
阶段1: 输入分析
- Sequence annotated (CDRs, frameworks)
- Species identified
- Target antigen characterized
- Clinical precedents identified
- 序列已注释(CDR、框架区)
- 物种已识别
- 靶点抗原已表征
- 临床先例已查询
Phase 2: Humanization
阶段2: 人源化
- Germline genes identified (IMGT)
- Framework selected
- CDR grafting designed
- Backmutations analyzed
- ≥2 humanized variants designed
- 种系基因已识别(IMGT)
- 框架区已选择
- CDR移植已设计
- 回复突变已分析
- 已设计≥2种人源化变体
Phase 3: Structure
阶段3: 结构分析
- AlphaFold structure predicted
- CDR conformations analyzed
- Epitope mapped
- Structural quality assessed
- AlphaFold结构已预测
- CDR构象已分析
- 表位已定位
- 结构质量已评估
Phase 4: Affinity
阶段4: 亲和力优化
- Current affinity estimated
- Affinity mutations proposed
- CDR optimization strategies identified
- Testing plan outlined
- 当前亲和力已预估
- 亲和力突变已建议
- CDR优化策略已识别
- 测试方案已制定
Phase 5: Developability
阶段5: 成药性评估
- Aggregation assessed
- PTM sites identified
- Stability predicted
- Expression predicted
- Overall score calculated (0-100)
- 聚集性已评估
- PTM位点已识别
- 稳定性已预测
- 表达量已预测
- 已计算综合成药性评分(0-100)
Phase 6: Immunogenicity
阶段6: 免疫原性预测
- T-cell epitopes predicted (IEDB)
- Immunogenicity score calculated
- Deimmunization strategy proposed
- Clinical precedent comparison
- T细胞表位已预测(IEDB)
- 免疫原性评分已计算
- 去免疫原化策略已建议
- 临床先例已对比
Phase 7: Manufacturing
阶段7: 生产可行性
- Expression system assessed
- Purification strategy outlined
- Formulation recommended
- CMC timeline estimated
- 表达系统已评估
- 纯化策略已制定
- 制剂配方已推荐
- CMC周期已预估
Phase 8: Final Report
阶段8: 最终报告
- Ranked variant list
- Top candidate recommended
- Experimental validation plan
- Backup variants identified
- Next steps outlined
- 变体排名列表已生成
- 最优候选变体已推荐
- 实验验证方案已制定
- 备份变体已识别
- 下一步计划已制定
Tool Reference
工具参考
IMGT Tools
IMGT工具
- : Search germline genes (IGHV, IGKV, etc.)
IMGT_search_genes - : Get germline sequences
IMGT_get_sequence - : Database information
IMGT_get_gene_info
- : 搜索种系基因(IGHV、IGKV等)
IMGT_search_genes - : 获取种系序列
IMGT_get_sequence - : 数据库信息查询
IMGT_get_gene_info
Antibody Databases
抗体数据库
- : Search antibody structures
SAbDab_search_structures - : Get structure details
SAbDab_get_structure - : Search by name
TheraSAbDab_search_therapeutics - : Search by target antigen
TheraSAbDab_search_by_target
- : 搜索抗体结构
SAbDab_search_structures - : 获取结构详情
SAbDab_get_structure - : 按名称搜索临床抗体
TheraSAbDab_search_therapeutics - : 按靶点抗原搜索
TheraSAbDab_search_by_target
Immunogenicity
免疫原性工具
- : Search epitopes
iedb_search_epitopes - : B-cell epitopes
iedb_search_bcell - : MHC-II epitopes
iedb_search_mhc - : Citations
iedb_get_epitope_references
- : 搜索表位
iedb_search_epitopes - : B细胞表位查询
iedb_search_bcell - : MHC-II表位查询
iedb_search_mhc - : 引用文献查询
iedb_get_epitope_references
Structure & Target
结构与靶点工具
- : Structure prediction
AlphaFold_get_prediction - : Target info
UniProt_get_protein_by_accession - : Experimental structures
PDB_get_structure
- : 结构预测
AlphaFold_get_prediction - : 靶点信息查询
UniProt_get_protein_by_accession - : 实验结构获取
PDB_get_structure
Systems Biology (for Bispecifics)
系统生物学工具(双特异性抗体)
- : Protein interactions
STRING_get_interactions - : Pathway analysis
STRING_get_enrichment
- : 蛋白质相互作用分析
STRING_get_interactions - : 通路分析
STRING_get_enrichment
Special Considerations
特殊考量
Bispecific Antibody Engineering
双特异性抗体工程
- Use STRING tools to identify co-expressed targets
- Design separate binding arms for each target
- Consider asymmetric formats (e.g., CrossMAb, DuoBody)
- Assess aggregation risk (higher for bispecifics)
- 使用STRING工具识别共表达靶点
- 为每个靶点设计独立的结合臂
- 考虑不对称格式(如CrossMAb、DuoBody)
- 评估聚集风险(双特异性抗体风险更高)
pH-Dependent Binding
pH依赖性结合
- Add His residues at interface (pKa ~6.0)
- Target: Bind at pH 7.4, release at pH 6.0
- Improves PK via FcRn recycling
- Useful for tumor targeting (acidic microenvironment)
- 在结合界面添加组氨酸残基(pKa~6.0)
- 目标: pH7.4下结合,pH6.0下解离
- 通过FcRn循环改善药代动力学
- 适用于肿瘤靶向(酸性微环境)
Affinity Ceiling
亲和力上限
- Most therapeutic antibodies: KD 0.1-10 nM
- <0.1 nM: May cause target-mediated clearance
- 1-5 nM: Sweet spot for most targets
- Balance affinity vs. developability
- 大多数治疗性抗体的KD值范围: 0.1-10 nM
- <0.1 nM: 可能导致靶点介导的清除
- 1-5 nM: 大多数靶点的最优范围
- 平衡亲和力与成药性
undefined